

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 267/14, A61K 31/55, C07D 413/06, C07F 9/38, C07D 413/14, C07F 9/40, A61K 31/66	A1	(11) International Publication Number: WO 97/10224 (43) International Publication Date: 20 March 1997 (20.03.97)
(21) International Application Number: PCT/JP96/02596 (22) International Filing Date: 12 September 1996 (12.09.96) (30) Priority Data: 7/235457 13 September 1995 (13.09.95) JP (71) Applicant (for all designated States except US): TAKEDA CHEMICAL INDUSTRIES, LTD. [JP/JP]; 1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka 541 (JP). (72) Inventors; and (75) Inventors/Applicants (for US only): YUKIMASA, Hidefumi [JP/JP]; 683-3, Kiderahigashiguchicho, Nara-shi, Nara 630 (JP). SUGIYAMA, Yasuo [JP/JP]; 7-2, Daiwahigashi 5- chome, Kawanishi-shi, Hyogo 666-01 (JP). TOZAWA, Ryuichi [JP/JP]; 30-14-303, Nagatakita 1-chome, Minami- ku, Yokohama-shi, Kanagawa 232 (JP). (74) Agents: ASAHINA, Tadao et al.; Osaka Plant of Takeda Chemical Industries, Ltd., 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka-shi, Osaka 532 (JP).		(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>

(54) Title: BENZOXAZEPINE COMPOUNDS, THEIR PRODUCTION AND USE AS LIPID LOWERING AGENTS**(57) Abstract**

This invention provides new benzoxazepine compounds represented by formula (I), wherein R stands for a lower alkyl group optionally substituted with a hydroxyl group, X stands for an optionally substituted carbamoyl group or an optionally substituted heterocyclic group having a deprotonatable hydrogen atom, R₁ stands for a lower alkyl group and W stands for a halogen atom having activities of lowering cholesterol-level and lowering triglyceride-level, and being useful for prophylaxis and therapy of hyperlipidemia.

**(I)**

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

DESCRIPTION

BENZOXAZEPINE COMPOUNDS, THEIR PRODUCTION AND USE AS LIPID LOWERING AGENTS

Technical Field

5 This invention relates to a benzoxazepine compound having an activity of lowering cholesterol-level and an activity of lowering triglyceride-level and useful for prophylaxis and therapy of hyperlipemia.

10 Background Art

 Abnormal increase of concentrations of lipids in plasma is called "hyperlipidemia" or "hyperlipemia". Serum lipids include cholesterol (cholesterol ester, free cholesterol), phospholipid (lecithin,
15 sphingomyelin, etc.), triglyceride (neutral fat), free fatty acid and other sterols. Increase of cholesterol and triglyceride is especially taken up as a problem from the clinical viewpoint [cf. Common Disease Series No.19 Koshikessho (hyperlipemia) compiled by Haruo
20 Nakamura, published by Nankodo].

 Therefore, adequate control of lipid concentration in blood is remarkably important for the prophylaxis or therapy of various diseases related to arteriosclerosis typically exemplified by ischemic heart disease and
25 cerebral infarction. And, hypertriglyceridemia is considered to accompany pancreatic disorders.

 As pharmaceutical compositions for lowering cholesterol in blood, attention has been drawn to those for controlling the biosynthesis of cholesterol,
30 besides those of inhibiting its absorption by binding bile acid including, among others, cholestyramine, colestipol (for example, USP 4027009), and those of suppressing the intestinal absorption of cholesterol by inhibiting acyl coenzyme A cholesterol acyl transferase
35 (ACAT) including melinamide (French Patent No.1476569). As pharmaceutical preparations for controlling the

biosynthesis of cholesterol, lovastatin (USP 4231938), simvastatin (USP 4444784), pravastatin (USP 4346227), etc., which are capable of inhibiting especially 3-hydroxy-3-methyl glutaryl coenzyme (HMG-CoA) reductase, are provided for medicinal use. However, when HMG-CoA reductase is inhibited, not only the biosynthesis of cholesterol but the biosynthesis of some other components such as ubiquinone, dolichol and heme A, which are necessary for the living body, is also inhibited, so that occurrences of undesirable side effects to be caused thereby are feared.

While, as agents of lowering triglyceride, fibrinoic acid type compounds, for example, clofibrate (UK Patent 860303) and fenofibrate (German Patent 2250327), are provided for medicines, they are prohibited to use together with statin type compounds for the fear of causing liver-toxicity.

Squalene synthetase is an enzyme taking part in the essential stage of the cholesterol biosynthetic pathway. This enzyme catalyzes the reductive dimerization of two molecules of farnesyl pyrophosphate to form squalene.

On the other hand, the compounds expected as inhibitors of cholesterol biosynthesis by inhibiting squalene synthetase are disclosed in Journal of Medicinal Chemistry, Vol.51, No.10, pp.1869-1871, 1988, JPA H1(1989)-213288, JPA H2(1990)-101088, JPA H2(1990)-235820, JPA H2(1990)-235821, JPA H3(1991)-20226, JPA H3(1991)-68591, JPA H3(1991)-148288, and USP 5,019,390, USP 5,135,935, WO9215579 and WO9309115.

Incidentally, hyperlipemia is also called "hyperlipoproteinemia" and is classified into the following six types (WHO classification) taking lipoproteins into consideration.

Type I : hyperchylomicronemia showing increase of chylomicrons,

Type IIa : hyperLDLemia (hypercholesterolemia) showing increase of low-density lipoprotein (LDL),

Type IIb : composite hyperlipemia showing increase of LDL and very-low-density lipoprotein (VLDL),

5 Type III : abnormal β lipoproteinemia showing the presence of β very-low-density lipoprotein (β VLDL),

Type IV : endogenous hypertriglycerolemia, and

Type V : mixed type hyperlipemia showing increase of VLDL and chylomicrons.

10


Disclosure of Invention

Through intensive investigations from the above viewpoints, the present inventors synthesized, for the first time, a 4,1-benzoxazepine compound with the
15 characteristic feature having specific substituents at 1-, 3-, 5- and 7-positions, and found that this compound has unexpectedly excellent lipid-level lowering activity based on the specific chemical structure, thus accomplishing the present invention.

20 More specifically, the present invention relates to:


(1) a compound represented by the formula (I)

25



30 wherein R stands for a lower alkyl group optionally substituted by hydroxyl group which may be substituted, X stands for an optionally substituted carbamoyl group or an optionally substituted heterocyclic group having a deprotonatable hydrogen atom, R₁ stands for a lower
35 alkyl group and W stands for a halogen atom, or a salt thereof,

- (2) the compound of (1) defined above, wherein R is C₁₋₆ alkyl which may have 1 to 3 substituents selected from the group consisting of hydroxyl, acetyloxy, propionyloxy, t-butoxycarbonyloxy, palmitoyloxy, dimethylaminoacetyloxy and 2-aminopropionyloxy,
- (3) the compound of (1) defined above, wherein R is C₃₋₆ branched alkyl which has 1 to 3 substituents selected from the group consisting of hydroxyl, acetyloxy, propionyloxy, t-butoxycarbonyloxy, palmitoyloxy, dimethylaminoacetyloxy and 2-aminopropionyloxy,
- (4) the compound of (1) defined above, wherein R is 2,2-dimethyl-3-hydroxypropyl, 3-hydroxy-2-hydroxymethyl-2-methylpropyl, 3-acetoxy-2,2-dimethylpropyl, 3-acetoxy-2-hydroxymethyl-2-methylpropyl or 3-acetoxy-2-acetoxymethyl-2-methylpropyl,
- (5) the compound of (1) defined above, wherein R₁ is methyl,
- (6) the compound of (1) defined above, wherein W is chlorine atom,
- (7) the compound of (1) defined above, wherein X is a carbamoyl group represented by the formula



- wherein R₂ and R₃ are independently
- (i) hydrogen,
 - (ii) optionally substituted hydrocarbon group,
 - (iii) optionally substituted heterocyclic group,
- or
- (iv) acyl group
- or R₂ and R₃ may form an optionally substituted 5 to 6 membered ring together with the adjacent nitrogen atom, said ring may contain 1 to 4 hetero atoms selected from nitrogen, oxygen and sulfur in addition to said nitrogen atom,

(8) the compound of (7) defined above, wherein R_2 is hydrogen or C_{1-7} alkyl, R_3 is

1) a hydrocarbon group selected from the group consisting of

- 5 (a) C_{1-7} alkyl,
- (b) C_{3-7} cycloalkyl,
- (c) C_{2-6} alkenyl,
- (d) C_{6-10} aryl and
- (e) C_{6-10} aryl- C_{1-4} alkyl,

10 wherein each of said groups (a), (b) and (c) may have 1 to 4 substituents selected from the group consisting of

- (i) carboxyl which may be esterified with C_{1-6} alkyl or C_{6-10} aryl- C_{1-4} alkyl,
- (ii) phosphono group which may be mono- or di-substituted by C_{1-6} alkyl or C_{2-7} alkanoyloxy- C_{1-6} alkyl,
- 15 (iii) sulfo group,
- (iv) sulfonamido which may be substituted by C_{1-6} alkyl or C_{6-10} aryl- C_{1-4} alkyl,
- 20 (v) hydroxyl group which may be alkylated with C_{1-3} alkyl,
- (vi) sulfhydryl group which may be alkylated with C_{1-3} alkyl,
- (vii) carbamoyl,
- 25 (viii) phenyl which may have 1 to 5 substituents selected from the group consisting of hydroxy, chlorine, fluorine, aminosulfonyl and amino which may be mono or di-substituted by C_{1-3} alkyl,
- (ix) amino which may be mono- or di-substituted by
- 30 C_{1-3} alkyl,
- (x) cyclic amino group selected from the group consisting of piperidyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, piperazinyl, 4-methylpiperazinyl, 4-benzylpiperazinyl, 4-phenylpiperazinyl, 1,2,3,4-tetrahydroisquinolinyl
- 35

- and phthalimido, each of said group may be substituted by C₁₋₃ alkyl, benzyl or phenyl and (xi) 5- to 6-membered heterocyclic group selected from the group consisting of pyridinyl, imidazolyl, indolyl and tetrazolyl, and each of said group (d) and (e) may have 1 to 4 substituents selected from the group consisting of (i) carboxyl which may be esterified by C₁₋₄ alkyl, (ii) phosphono which may be mono- or di-substituted by C₁₋₆ alkyl or C₂₋₇ alkanoyloxy-C₁₋₆ alkyl, (iii) sulfo, (iv) C₁₋₄ alkylsulfonyl, C₆₋₁₀ arylsulfonyl or C₆₋₁₀ aryl-C₁₋₄ alkylsulfonyl, (v) sulfonamido which may be substituted by C₁₋₆ alkyl or C₆₋₁₀ aryl-C₁₋₄ alkyl, (vi) C₁₋₃ alkyl group which may be substituted by carboxyl group optionally esterified with C₁₋₄ alkyl, phosphono which may be mono- or di-substituted by C₁₋₆ alkyl, sulfo or sulfonamido which may be substituted by C₁₋₆ alkyl or C₆₋₁₀ aryl-C₁₋₄ alkyl and (v) halogen,
- 2) a heterocyclic group selected from the group consisting of tetrazolyl, 4,5-dihydro-5-oxo-1,2,4-oxadiazolyl, 4,5-dihydro-5-thioxo-1,2,4-oxadiazolyl, 2,3-dihydro-3-oxo-1,2,4-oxadiazolyl, 2,3-dihydro-3-thioxo-1,2,4-oxadiazolyl, 3,5-dioxo-1,2,4-oxadiazolidinyl, 4,5-dihydro-5-oxo-isoxazolyl, 4,5-dihydro-5-thioxo-isoxazolyl, 2,3-dihydro-2-oxo-1,3,4-oxadiazolyl, 2,3-dihydro-3-oxo-1,2,4-tetrazolyl and 2,3-dihydro-3-thioxo-1,2,4-tetrazolyl or the salt thereof,
- 3) an acyl group selected from the group consisting of (i) C₂₋₇ alkanoyl which may be substituted by 1 to


- 2 halogen atoms,
(ii) C₆₋₁₀ arylsulfonyl,
(iii) C₁₋₄ alkylsulfonyl, and
(iv) C₆₋₁₀ aryl-C₁₋₄ alkylsulfonyl,
- 5 each of said group (ii), (iii) and (iv) may have 1 to 4 substituents selected from the group consisting of C₁₋₃ alkyl, C₁₋₃ alkoxy and halogen, or R₂ and R₃ together with adjacent nitrogen form a 5- or 6- membered cyclic amino selected from the group
- 10 consisting of piperazinyl, piperidyl, pyrrolidinyl, 2-oxo-piperazinyl, 2,6-dioxopiperazinyl, morpholinyl and thiomorpholinyl, each of said group may have 1 to 4 substituents selected from the group consisting of
- (A) hydroxyl which may be substituted with C₁₋₃ alkyl
- 15 or C₂₋₇ alkanoyl,
(B) carboxyl which may be substituted with C₁₋₆ alkyl or C₆₋₁₀ aryl-C₁₋₄ alkyl,
(C) phosphono which may be mono- or di-substituted by C₁₋₆ alkyl or C₂₋₇ alkanoyloxy-C₁₋₆ alkyl,
- 20 (D) sulfo,
(E) sulfonamide which may be substituted with C₁₋₆ alkyl or C₆₋₁₀ aryl-C₁₋₄ alkyl,
(F) C₁₋₆ alkyl or C₂₋₅ alkenyl which may be substituted by
- 25 (i) carboxyl group which may be esterified with C₁₋₆ alkyl or C₆₋₁₀ aryl-C₁₋₄ alkyl,
(ii) phosphono group which may be mono- or di substituted by C₁₋₆ alkyl or C₂₋₇ alkanoyloxy-C₁₋₆ alkyl,
- 30 (iii) sulfo group,
(iv) sulfonamido which may be substituted by C₁₋₆ alkyl or C₆₋₁₀ aryl-C₁₋₄ alkyl,
(v) hydroxyl group which may be alkylated with C₁₋₃ alkyl or C₂₋₇ alkanoyl,
- 35 (vi) sulfhydryl group which may be alkylated with

- C₁₋₃ alkyl,
(vii) carbamoyl,
(viii) phenyl which may have 1 to 5 substituents
selected from the group consisting of hydroxy,
5 halogen, aminosulfonyl and amino which may be
substituted with C₁₋₃ alkyl and
(ix) amino which may be mono- or di-substituted by
C₁₋₃ alkyl, or
(x) tetrazolyl,
10 (G) amino which may be mono- or di-substituted with
C₁₋₃ alkyl,
(H) cyclic amino group selected from the group
consisting of piperidyl, pyrrolidinyl, morpholinyl,
thiomorpholinyl, 4-methylpiperazinyl, 4-
15 benzympiperazinyl, and 4-phenyl- piperazinyl,
(I) cyano,
(J) carbamoyl,
(K) oxo,
(L) heterocyclic group selected from tetrazolyl and
20 2,5-dihydro-5-oxo-1,2,4-oxazolyl,
(M) carbamoyl substituted with C₁₋₄ alkylsulfonyl, C₆₋₁₀
arylsulfonyl or C₆₋₁₀ aryl-C₁₋₄ alkylsulfonyl,
(N) sulfhydryl which may be alkylated with C₁₋₃ alkyl,
(O) phenyl which may have 1 to 5 substituents selected
25 from hydroxyl, halogen, aminosulfonyl and amino which
may be substituted with C₁₋₃ alkyl,
or the salt thereof,
(9) the compound of (7) defined above, wherein R₂ and
R₃ together with the adjacent nitrogen of the carbamoyl
30 form a 5 to 6-membered ring selected from the group
consisting of 1-piperazinyl, piperidyl, 1-pyrrolidinyl,
2-oxo-piperazinyl and 2,6-dioxo-piperazinyl, each of
the said group may have 1 to 2 substituents of C₁₋₆
alkyl which may be substituted by
35 (i) carboxyl which may be esterified with C₁₋₆

- alkyl or C₆₋₁₀ aryl-C₁₋₄ alkyl,
(ii) phosphono group which may be mono- or di-substituted by C₁₋₆ alkyl or C₂₋₇ alkanoyloxy-C₁₋₆ alkyl,
5 (iii) sulfo group,
(iv) sulfonamido which may be substituted by C₁₋₆ alkyl or C₆₋₁₀ aryl-C₁₋₄ alkyl,
(v) hydroxyl group which may be alkylated by C₁₋₃ alkyl,
10 (vi) sulfhydryl which may be alkylated by C₁₋₃ alkyl,
(vii) carbamoyl,
(viii) phenyl which may have 1 to 5 substituents selected from the group consisting of hydroxy,
15 halogen, aminosulfonyl and amino which may be substituted with C₁₋₃ alkyl,
(ix) amino which may be mono- or di-substituted by C₁₋₃ alkyl, or
(x) tetrazolyl,
20 (10) the compound of (7) defined above, wherein R₂ is hydrogen or C₁₋₇ alkyl and R₃ is C₁₋₄ alkylsulfonyl,
(11) The compound of term (1) defined above, wherein the heterocyclic group represented by X is tetrazolyl, 4,5-dihydro-5-oxo-1,2,4-oxadiazolyl, 4,5-dihydro-5-thioxo-1,2,4-oxadiazolyl, 2,3-dihydro-3-oxo-1,2,4-oxadiazolyl, 2,3-dihydro-3-thioxo-1,2,4-oxadiazolyl, 3,5-dioxo-1,2,4-oxadiazolidinyl, 4,5-dihydro-5-oxo-isoxazolyl, 4,5-dihydro-5-thioxo-isoxazolyl, 2,3-dihydro-2-oxo-1,3,4-oxadiazolyl, 2,3-dihydro-3-oxo-1,2,4-tetrazolyl, or 2,3-dihydro-3-thioxo-1,2,4-tetrazolyl,
25 (12) the compound of (1) defined above, wherein R₁ is methyl, W is chlorine atom,
R is C₃₋₆ branched alkyl which has 1 to 3 substituents
30 selected from the group consisting of hydroxyl,


acetyloxy, propionyloxy, t-butoxycarbonyloxy, palmitoyloxy, dimethylaminoacetyloxy and 2-aminopropionyloxy, and X is the carbamoyl group represented by a formula

5




wherein R_2' is hydrogen or C_{1-7} alkyl and R_3' is C_{1-4} alkyl,
 (13) the compound of (1) defined above, wherein R_1 is methyl, W is chlorine atom, R is C_{3-6} branched alkyl which has 1 to 3 substituents selected from the group consisting of hydroxyl, acetyloxy, propionyloxy, t-butoxycarbonyloxy, palmitoyloxy, dimethylaminoacetyloxy and 2-aminopropionyloxy, and X is the carbamoyl group represented by a formula

20



wherein R' is hydrogen or C_{1-7} alkyl and n is an integer from 1 to 5,
 (14) the compound of (1) defined above, wherein R_1 is methyl, W is chlorine atom, R is C_{3-6} branched alkyl which has 1 to 3 substituents selected from the group consisting of hydroxyl, acetyloxy, propionyloxy, t-butoxycarbonyloxy, palmitoyloxy, dimethylaminoacetyloxy and 2-aminopropionyloxy, and X is a carbamoyl group represented by the formula

30



- 5 wherein R'' is hydrogen or C₁₋₄ alkyl,
 (15) the compound of (1) defined above, wherein
 R₁ is methyl, W is chlorine atom,
 R is C₃₋₆ branched alkyl which has 1 to 3 substituents
 selected from the group consisting of hydroxyl,
 10 acetyloxy, propionyloxy, t-butoxycarbonyloxy,
 palmitoyloxy, dimethylaminoacetyloxy and 2-
 aminopropionyloxy, and X is tetrazolyl,
 (16) the compound of (1) defined above, which is
 (3R,5S)-N-methanesulfonyl-7-chloro-5-(2,3-
 15 dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-2-
 oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetamide,
 (3R,5S)-N-methanesulfonyl-7-chloro-5-(2,3-
 dimethoxyphenyl)-1-(3-hydroxy-2-hydroxymethyl-2-
 methylpropyl)-2-oxo-1,2,3,5-tetrahydro-4,1-
 20 benzoxazepine-3-acetamide,
 (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-
 2-hydroxymethyl-2-methylpropyl)-2-oxo-N-[2-(pyrrolidin-
 1-yl)ethyl]-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-
 acetamide,
 25 (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-
 2,2-dimethylpropyl)-2-oxo-N-[2-(pyrrolidin-1-yl)ethyl]-
 1,2,3,5-tetrahydro-4,1-benzazepine-3-acetamide,
 or a salt thereof,
 (17) the compound of (1) defined above, which is
 30 (3R,5S)-N-methanesulfonyl-1-(3-acetoxy-2,2-
 dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-
 1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetamide,
 (3R,5S)-N-methanesulfonyl-1-(3-acetoxy-2-acetoxymethyl-
 2-methylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-
 35 1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetamide,
 N-[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-

- (2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]piperidine-4-acetic acid,
N-[(3R,5S)-1-(3-acetoxy-2-acetoxymethyl-2-methylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]piperidine-4-acetic acid,
5 N-[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]piperidine-4-acetic acid ethyl ester,
10 N-[(3R,5S)-1-(3-acetoxy-2-acetoxymethyl-2-methylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]piperidine-4-acetic acid ethyl ester or a salt thereof,
15 (18) the compound of (1) defined above, which is
(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-1,2,3,5-tetrahydro-3-[1H(or3H)-tetrazol-5-yl]methyl-4,1-benzoxazepine-3-one,
20 (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2-hydroxymethyl-2-methylpropyl)-1,2,3,5-tetrahydro-3-[1H(or3H)-tetrazol-5-yl]methyl-4,1-benzoxazepine-3-one,
(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-3-[1H(or3H)-tetrazol-5-yl]methyl-4,1-benzoxazepine-3-one,
25 (3R,5S)-1-(3-acetoxy-2-acetoxymethyl-2-methylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-3-[1H(or3H)-tetrazol-5-yl]methyl-4,1-benzoxazepine-3-one or a salt thereof,
30 (19) the compound of (1) defined above, which is
(3R,5S)-7-Chloro-5-(2,3-dimethoxyphenyl)-1-neopentyl-2-oxo-N-[2-(pyrrolidin-1-yl)ethyl]-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetamide or the salt thereof,
(20) the compound of (1) defined above, wherein
35 R is a lower alkyl group which may be substituted with one or two hydroxyl groups,

X is carbamoyl group, which may have substituent(s) on the nitrogen atom of the carbamoyl group,

said substituent being

(1) hydrocarbon selected from the group consisting of

- 5 (a) C₁₋₇ alkyl,
- (b) C₃₋₇ cycloalkyl,
- (c) C₂₋₆ alkenyl,
- (d) C₆₋₁₀ aryl and
- (e) C₇₋₁₄ arylalkyl (C₆₋₁₀ aryl-C₁₋₄ alkyl),

10 wherein each of said groups (a), (b) and (c) may have 1 to 4 substituents selected from the group consisting of

- (i) carboxyl which may be esterified with C₁₋₆ alkyl or C₇₋₁₀ arylalkyl (phenyl-C₁₋₄ alkyl),
- (ii) phosphono group,
- 15 (iii) sulfo group,
- (iv) sulfonamido which may be substituted by C₁₋₆ alkyl or C₇₋₁₀ arylalkyl (phenyl-C₁₋₄ alkyl),
- (v) hydroxyl group which may be alkylated with C₁₋₃ alkyl,
- 20 (vi) sulfhydryl group which may be alkylated with C₁₋₃ alkyl,
- (vii) carbamoyl,
- (viii) phenyl which may have substituent(s) selected from the group consisting of hydroxyl,
- 25 chlorine, fluorine, aminosulfonyl and amino which may be mono or di-substituted by C₁₋₃ alkyl,
- (ix) amino which may be mono- or di-substituted by C₁₋₃ alkyl,
- (x) cyclic amino group selected from the group consisting of piperidyl, pyrrolidinyl,
- 30 morpholinyl, thiomorpholinyl, piperazinyl, 4-methylpiperazinyl, 4-benzylpiperazinyl and 4-phenylpiperazinyl, each of said group may be substituted by C₁₋₃ alkyl, benzyl or phenyl and
- 35 (xi) 5- to 6-membered heterocyclic group selected

- from the group consisting of pyridinyl,
imidazolyl, indolyl and tetrazolyl,
, and each of said group (d) and (e) may have 1 to 4
substituents selected from the group consisting of
- 5 (i) carboxyl which may be esterified by C₁₋₄ alkyl,
(ii) phosphono,
(iii) sulfo,
(iv) sulfonamido which may be substituted by C₁₋₆
alkyl or C₇₋₁₀ arylalkyl (phenyl-C₁₋₄ alkyl),
10 (v) C₁₋₃ alkyl group which may be substituted by
carboxyl group optionally esterified with C₁₋₄
alkyl, phosphono, sulfo, or sulfonamido optionally
substituted with C₁₋₆ alkyl or C₇₋₁₀ arylalkyl
(phenyl-C₁₋₄ alkyl), and
15 (vi) halogen,
- (2) a heterocyclic group selected from the group
consisting of tetrazolyl, 4,5-dihydro-5-oxo-1,2,4-
oxadiazolyl, 4,5-dihydro-5-thioxo-1,2,4-oxadiazolyl,
2,3-dihydro-3-oxo-1,2,4-oxadiazolyl, 2,3-dihydro-3-
20 thioxo-1,2,4-oxadiazolyl, 3,5-dioxo-1,2,4-
oxadiazolidinyl, 4,5-dihydro-5-oxo-isoxazolyl, 4,5-
dihydro-5-thioxo-isoxazolyl, 2,3-dihydro-2-oxo-1,3,4-
oxadiazolyl, 2,3-dihydro-3-oxo-1,2,4-tetrazolyl and
2,3-dihydro-3-thioxo-1,2,4-tetrazolyl,
- 25 (3) an acyl group selected from the group consisting of
(i) C₂₋₇ alkanoyl which may be substituted by 1 to
2 halogen atoms,
(ii) C₆₋₁₀ arylsulfonyl,
(iii) C₁₋₄ alkylsulfonyl, and
30 (iv) C₇₋₁₄ arylalkylsulfonyl (C₆₋₁₀ aryl-C₁₋₄
alkylsulfonyl),
each of said group (ii), (iii) and (iv) may have 1 to 4
substituents selected from the group consisting of C₁₋₃
alkyl, C₁₋₃ alkoxy and halogen or
35 (4) cyclic amino carbonyl group, the cyclic amino group

being selected from the group consisting of
piperazinyl, piperidyl, pyrrolidinyl, 2-oxo-
piperazinyl, 2,6-dioxopiperazinyl, morpholinyl and
thiomorpholinyl,

5 each of said group may have 1 to 4 substituents
selected from the group consisting of

- (i) hydroxyl,
- (ii) carboxyl optionally esterified with C₁₋₄
alkyl,
- 10 (iii) phosphono,
- (iv) sulfo,
- (v) sulfonamido optionally substituted with C₁₋₆
alkyl or C₇₋₁₀ arylalkyl (phenyl-C₁₋₄ alkyl),
- (vi) C₁₋₃ alkyl or C₂₋₅ alkenyl optionally
15 substituted with (i), (ii), (iii), (iv) or (v)
defined above,
- (vii) amino optionally mono- or di-substituted
with C₁₋₃ alkyl,
- (viii) cyclic amino group selected from piperidyl,
20 pyrrolidinyl, morpholinyl, thiomorpholinyl, 4-
methylpiperazinyl, 4-benzylpiperazinyl and 4-
phenylpiperazinyl,
- (ix) cyano,
- (x) carbamoyl,
- 25 (xi) oxo,
- (xii) C₁₋₃ alkoxy,
- (xiii) heterocyclic group selected from tetrazolyl
and 2,5-dihydro-5-oxo-1,2,4-oxazolyl, and
- (xiv) carbamoyl substituted with C₆₋₁₀
30 arylsulfonyl, C₁₋₄ alkylsulfonyl or C₇₋₁₀
arylalkylsulfonyl (phenyl-C₁₋₄ alkylsulfonyl),
- (21) a composition which comprises the compound of (1)
defined above and a pharmaceutically acceptable
carrier,
- 35 (22) a pharmaceutical composition for inhibiting

- squalene synthetase, which comprises the compound of
(1) defined above and a pharmaceutically acceptable
carrier,
- 5 (23) a pharmaceutical composition for lowering the
level of triglyceride, which comprises the compound of
(1) defined above and a pharmaceutically acceptable
carrier,
- (24) a pharmaceutical composition for lowering the
lipid-level, which comprises the compound of (1)
10 defined above and a pharmaceutically acceptable
carrier,
- (25) a pharmaceutical composition for prophylaxis or
therapy of hyperlipidaemia, which comprises the
compound of (1) defined above and a pharmaceutically
15 acceptable carrier,
- (26) use of the compound of (1) defined above for
manufacturing a pharmaceutical composition,
- (27) use of the compound of (1) defined above for
manufacturing a squalene synthetase inhibitor,
- 20 (28) use of the compound of (1) defined above for
manufacturing a pharmaceutical composition for lowering
the level of triglyceride,
- (29) use of the compound of (1) defined above for
manufacturing a pharmaceutical composition for lowering
25 the lipid-level,
- (30) use of the compound of (1) defined above for
manufacturing a pharmaceutical composition for
prophylaxis or therapy of hyperlipidaemia or coronary
sclerosis,
- 30 (31) a method for inhibiting squalene synthetase in a
mammal comprising administering an effective amount of
the compound of (1) defined above to said mammal,
- (32) a method for lowering the level of triglyceride in
a mammal comprising administering an effective amount
35 of the compound of (1) defined above to said mammal,
- (33) a method for lowering the lipid-level in a mammal

comprising administering an effective amount of the compound of (1) defined above to said mammal,


(34) a method for prophylaxis or therapy of hyperlipidaemia or coronary sclerosis in a mammal

comprising administering an effective amount of the compound of (1) defined above to said mammal,

(35) a process for producing the compound or the salt thereof of (1) defined above, wherein X is an


optionally substituted carbamoyl group, which comprises

reacting a compound of the formula:



wherein the symbols are the same as defined in term

(1), or a salt thereof with a compound of the formula:



wherein the symbols are the same as defined in (7), or a salt thereof,

(36) the compound of (1) defined above, wherein R is 2,2-dimethyl-3-hydroxypropyl.

As the lower alkyl group shown by R, mention is made of C₁₋₆ alkyl such as methyl, ethyl, n-propyl,

isopropyl, n-butyl, isobutyl, n-pentyl, isopentyl, neopentyl and hexyl. Above all, C₃₋₆ alkyl groups are preferable and C₄₋₅ alkyl groups are more preferable.

Especially, branched C₄₋₅ alkyl groups such as isobutyl and neopentyl are most preferable. The substituent of

lower alkyl group shown by R includes hydroxyl group which may be substituted with for example C₂₋₂₀

alkanoyl, C₁₋₇ alkyl and so on. Specifically, the substituent of lower alkyl group shown by R includes hydroxyl, acetyloxy, propionyloxy, t-butoxycarbonyloxy, palmitoyloxy, dimethylaminoacetyloxy and 2-aminopropionyloxy. The number of the above substituents ranges from 1 to 3.

Examples of R include 2,2-dimethyl-3-hydroxypropyl, 3-hydroxy-2-hydroxymethyl-2-methylpropyl, 3-acetoxy-2,2-dimethylpropyl, 3-acetoxy-2-hydroxymethyl-2-methylpropyl and 3-acetoxy-2-acetoxymethyl-2-methylpropyl.

The "optionally substituted carbamoyl group" is represented by the formula



The term "hydrocarbon group" described in the specification includes optionally substituted C₁₋₇ straight-chain or branched alkyl groups (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 1,1-dimethylethyl, n-pentyl, 3-methylbutyl, 2-methylbutyl, 1-methylbutyl, 1-ethylpropyl, n-hexyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 2-ethylbutyl, 1-ethylbutyl, neopentyl, hexyl and heptyl), optionally substituted C₃₋₇ cycloalkyl groups (e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cyclohexylmethyl), optionally substituted C₂₋₆ straight-chain or branched alkenyl groups (e.g. vinyl, allyl, isopropenyl, 2-methylallyl, 1-propenyl, 2-methyl-1-propenyl, 2-methyl-2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-ethyl-1-butenyl, 2-methyl-2-butenyl, 3-methyl-2-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 4-methyl-3-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl and 5-hexenyl), optionally substituted C₆₋₁₀ aryl groups (e.g. phenyl and naphthyl

groups) and optionally substituted C₆₋₁₀ aryl-C₁₋₄ alkyl groups (e.g. benzyl, phenethyl and naphthylmethyl).

Substituents of "optionally substituted C₁₋₇ straight-chain or branched alkyl groups, optionally substituted C₃₋₇ cycloalkyl groups and C₂₋₆ straight-chain or branched alkenyl groups" are exemplified by carboxyl groups optionally esterified with C₁₋₆ alkyl groups or C₆₋₁₀ aryl-C₁₋₄ alkyl groups (e.g. methyl, ethyl, propyl, isopropyl, butyl, t-butyl, phenyl and benzyl), phosphono group which may be mono- or di-substituted by C₁₋₆ alkyl such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, n-pentyl, isopentyl, neopentyl and hexyl, or C₂₋₇ alkanoyloxy-C₁₋₆ alkyl such as acetyloxy methyl and pivaloyloxymethyl, sulfo group, sulfonamido group optionally substituted with C₁₋₆ alkyl groups or C₆₋₁₀ aryl-C₁₋₄ alkyl groups (e.g. methyl, ethyl, propyl, isopropyl, butyl, t-butyl and benzyl), hydroxyl group and sulfhydryl group optionally alkylated with C₁₋₃ alkyl groups (e.g. methyl, ethyl and propyl), carbamoyl group, phenyl group optionally substituted with 1 to 5 substituents [e.g. hydroxyl group, chlorine, fluorine, aminosulfonyl group, and amino group optionally substituted with C₁₋₃ alkyl group (e.g. methyl, ethyl and propyl)], amino group optionally mono- or di-substituted with C₁₋₃ alkyl groups (e.g. methyl, ethyl and propyl), cyclic amino groups which may further have a hetero atom selected from oxygen and sulfur as the ring-forming atoms, and which may be substituted by C₁₋₃ alkyl, benzyl or phenyl, such as (piperidyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, piperazinyl, 4-methylpiperazinyl, 4-benzylpiperazinyl, 4-phenylpiperazinyl, 1,2,3,4-tetrahydroisoquinolinyl, and phthalimido) and aromatic 5- to 6-membered heterocyclic groups containing 1 to 4 hetero-atoms selected from N, O and S (e.g. pyridinyl,

imidazolyl, indolyl and tetrazolyl).

Further, examples of the substituents of C₆₋₁₀ aryl groups and C₆₋₁₀ aryl-C₁₋₄ alkyl groups as the substituents of the optionally substituted amino groups forming the carbamoyl group of "optionally substituted carbamoyl groups" shown by X include carboxyl groups optionally esterified with C₁₋₄ alkyl groups (e.g. methyl, ethyl, propyl and t-butyl groups), phosphono group which may be mono- or di-substituted by C₁₋₆ alkyl such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, n-pentyl, isopentyl, neopentyl and hexyl, or or C₂₋₇ alkanoyloxy-C₁₋₆ alkyl such as acetyloxy methyl and pivaloyloxymethyl, sulfo group, C₁₋₄ alkylsulfonyl (e.g. methylsulfonyl, ethylsulfonyl, n-propylsulfonyl, isopropylsulfonyl and n-butylsulfonyl), C₆₋₁₀ arylsulfonyl (e.g. phenylsulfonyl and naphthylsulfonyl) or C₆₋₁₀ aryl-C₁₋₄ alkylsulfonyl (e.g. benzylsulfonyl, phenethylsulfonyl and naphthylmethylsulfonyl), sulfonamido groups optionally substituted with C₁₋₆ alkyl groups or C₆₋₁₀ aryl-C₁₋₄ alkyl groups (e.g. methyl, ethyl, propyl, isopropyl, butyl, t-butyl and benzyl), and C₁₋₃ alkyl groups (e.g. methyl, ethyl, propyl and isopropyl) optionally substituted with (i) carboxyl groups optionally esterified with C₁₋₄ alkyl group (e.g. methyl, ethyl, propyl and butyl), (ii) phosphono group which may be mono- or di-substituted by C₁₋₆ alkyl such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, n-pentyl, isopentyl, neopentyl and hexyl, or C₂₋₇ alkanoyloxy-C₁₋₆ alkyl such as acetyloxymethyl and pivaloyloxymethyl, (iii) sulfo group and (iv) sulfonamido group optionally substituted with C₁₋₆ alkyl (e.g. methyl, ethyl, propyl, butyl, pentyl and hexyl) or C₆₋₁₀ aryl-C₁₋₄ alkyl (benzyl and phenethyl), and halogen (fluorine and chlorine).

The number of the substituents of "optionally

substituted hydrocarbon group" is 1 to 4, preferably 1 to 2.

Preferable examples of "optionally substituted heterocyclic groups" described in the specification include heterocyclic groups having deprotonizable hydrogen atom optionally having one or two, preferably one, substituents of substituents such as oxo group and thioxo groups. As such heterocyclic groups, 5- to 6-membered heterocyclic groups consisting of 1 to 4, preferably 2 to 3, hetero-atoms selected from S, O and N are preferable. Specifically, tetrazolyl, 4,5-dihydro-5-oxo-1,2,4-oxadiazolyl, 4,5-dihydro-5-thioxo-1,2,4-oxadiazolyl, 2,3-dihydro-3-oxo-1,2,4-oxadiazolyl, 2,3-dihydro-3-thioxo-1,2,4-oxadiazolyl, 3,5-dioxo-1,2,4-oxadiazolidinyl, 4,5-dihydro-5-oxo-isoxazolyl, 4,5-dihydro-5-thioxo-isoxazolyl, 2,3-dihydro-2-oxo-1,3,4-oxadiazolyl, 2,3-dihydro-3-oxo-1,2,4-tetrazolyl and 2,3-dihydro-3-thioxo-1,2,4-tetrazolyl are exemplified. Especially tetrazolyl is preferable.

The term "acyl group" described in the specification refers to carboxylic acid acyl groups derived from carboxylic acid (C_{2-7} carboxylic acid acyl group e.g. acetyl, propionyl, butyryl and benzoyl) and optionally substituted C_{6-10} arylsulfonyl groups, C_{1-4} alkylsulfonyl groups and C_{6-10} aryl- C_{1-4} alkylsulfonyl groups (e.g. methylsulfonyl, ethylsulfonyl, phenylsulfonyl, naphthylsulfonyl, phenylmethylsulfonyl, phenylethylsulfonyl, naphthylmethylsulfonyl and naphthylethylsulfonyl). As the substituents of aryl-, alkyl- and arylalkylsulfonyl groups, mention is made of, for example, C_{1-3} alkyl (e.g. methyl, ethyl and propyl), C_{1-3} alkoxy (e.g. methoxy, ethoxy and propoxy), halogen (chlorine, fluorine and bromine), and 1 to 4, preferably 1 to 2, of them may optionally be substituted at any substitutable position.

The above-mentioned carboxylic acid acyl groups

may optionally have 1 to 2 halogen atoms (chlorine, fluorine and bromine) as substituents.


The ring formed by R₂ and R₃ together with the adjacent nitrogen of the carbamoyl refers to optionally substituted 5- or 6-membered cyclic amino which may further have 1 to 3 hetero atoms selected from nitrogen, sulfur and oxygen as ring constituting atoms such as piperazinyl, piperidino, 1-pyrrolidinyl, 2-oxo-1-piperazinyl, 2,6-dioxo-1-piperazinyl, morpholinyl and thiomorpholinyl. These cyclic amino groups may optionally have 1 to 4, preferably 1 to 2, substituents. Examples of those substituents include hydroxyl group which may be substituted with C₁₋₃ alkyl or C₂₋₇ alkanoyl, carboxyl groups optionally esterified with a C₁₋₄ alkyl group (e.g. methyl, ethyl, propyl or t-butyl group) or C₆₋₁₀ aryl-C₁₋₄ alkyl, phosphono group which may be mono- or di-substituted by C₁₋₆ alkyl such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, n-pentyl, isopentyl, neopentyl and hexyl or C₂₋₇ alkanoyloxy-C₁₋₆ alkyl such as acetyloxymethyl and pivaloyloxymethyl, sulfo group and sulfonamido group optionally substituted with a C₁₋₆ alkyl group or a C₆₋₁₀ aryl-C₁₋₄ alkyl group (e.g. methyl, ethyl, propyl, isopropyl, butyl, t-butyl or benzyl), C₁₋₆ alkyl which may be substituted by

- (i) carboxyl group which may be esterified with C₁₋₆ alkyl, or C₆₋₁₀ aryl-C₁₋₄ alkyl,
- (ii) phosphono group which may be mono- or di substituted by C₁₋₆ alkyl or C₂₋₇ alkanoyloxy-C₁₋₆ alkyl,
- (iii) sulfo group,
- (iv) sulfonamido which may be substituted by C₁₋₆ alkyl or C₆₋₁₀ aryl-C₁₋₄ alkyl,
- (v) hydroxyl group which may be alkylated with C₁₋₃ alkyl or C₂₋₇ alkanoyl,

(vi) sulfhydryl group which may be alkylated with C₁₋₃ alkyl,
(vii) carbamoyl,
(viii) phenyl which may have 1 to 5 substituents
5 selected from the group consisting of hydroxy, halogen, aminosulfonyl, amino which may be substituted with C₁₋₃ alkyl and
(ix) amino which may be mono- or di-substituted by C₁₋₃ alkyl, or
10 (x) tetrazolyl,
and C₂₋₅ alkenyl group (e.g. vinyl and allyl) which may be substituted by the same group selected among (i) to (x) as described above for substituents of C₁₋₆ alkyl,
amino groups optionally mono- or di-substituted with
15 C₁₋₃ alkyl groups, cyclic amino groups derived from 5- or 6-membered cyclic amine which may further have a hetero atom selected from nitrogen, sulfur and oxygen, and which may be substituted by C₁₋₃ alkyl, benzyl or phenyl, such as piperidyl, pyrrolidinyl, morpholinyl,
20 thiomorpholinyl, 4-methylpiperazinyl, 4-benzylpiperazinyl and 4-phenylpiperazinyl, cyano group, carbamoyl group, oxo group, heterocyclic groups optionally substituted with an oxo group or thioxo group having such a deprotonizable hydrogen atom as
25 mentioned above (e.g. tetrazolyl and 2,5-dihydro-5-oxo-1,2,4-oxazolyl), carbamoyl groups substituted with C₁₋₄ alkylsulfonyl, C₆₋₁₀ arylsulfonyl and C₆₋₁₀ aryl-C₁₋₄ alkyl arylsulfonyl (methylsulfonyl, ethylsulfonyl, propylsulfonyl, butylsulfonyl, isopropylsulfonyl, t-butylsulfonyl, phenylsulfonyl and benzylsulfonyl),
30 sulfhydryl which may be alkylated with C₁₋₃ alkyl and phenyl which may have 1 to 5 substituents such as hydroxyl, halogen, aminosulfonyl and amino which may be substituted with C₁₋₃ alkyl.

35 Examples of "optionally substituted carbamoyl

group" shown by X include



10 Examples of R_2' and R' include hydrogen and C_{1-7} alkyl. Among them, hydrogen is preferable.

 Examples of R_3' include C_{1-4} alkyl such as methyl, ethyl, propyl and butyl.

15 Examples of C_{1-7} alkyl shown by R_2 , R_2' , R' are the same as those described in "hydrocarbon group".

 Examples of R'' include hydrogen and C_{1-4} alkyl. Among them, hydrogen is preferable.

 Examples of C_{1-4} alkyl shown by R_3' and R'' include methyl, ethyl, propyl, isopropyl, n-butyl and t-butyl.

20 Examples of n include 1, 2, 3, 4 and 5.

 Preferable examples of optionally substituted heterocyclic groups having deprotonizable hydrogen atom, shown by X, include N-containing (preferably 1 to 4 nitrogen atoms) 5- to 6-membered heterocyclic groups having Brønsted acid-like active proton, and those comprising 1 to 4, preferable 2 or 3, nitrogen atom, sulfur atom and oxygen atom, are preferable. As these substituents, mention is made of, for example, oxo group and thioxo group, and one or two, preferably one

25 substituents may be present. As "optionally substituted heterocyclic groups having deprotonizable hydrogen atom" shown by X, mention is made of, for example, those exemplified as "optionally substituted heterocyclic groups" as the substituents of the

30 "optionally substituted carbamoyl groups" shown by X, such as tetrazolyl, 2,5-dihydro-5-oxo-1,2,4-

35

oxadiazolyl.

As "lower alkyl groups" shown by R₁, mention is made of C₁₋₆ alkyl groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, pentyl and hexyl. Among them, C₁₋₃ alkyl groups are especially preferable. As R₁, methyl group is especially preferable from the viewpoint of pharmacological activity.

As "halogen atoms" shown by W, mention is made of chlorine, fluorine, bromine and iodine atom. Among them, chlorine atom is especially preferable.

Specifically the following compounds are preferable:

(3R,5S)-N-methanesulfonyl-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetamide,
(3R,5S)-N-methanesulfonyl-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2-hydroxymethyl-2-methylpropyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetamide,
(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2-hydroxymethyl-2-methylpropyl)-2-oxo-N-[2-(pyrrolidin-1-yl)ethyl]-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetamide,
(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-N-[2-(pyrrolidin-1-yl)ethyl]-1,2,3,5-tetrahydro-4,1-benzazepine-3-acetamide,
(3R,5S)-N-methanesulfonyl-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetamide,
(3R,5S)-N-methanesulfonyl-1-(3-acetoxy-2-acetoxymethyl-2-methylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetamide,
N-[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]piperidine-4-acetic acid,
N-[(3R,5S)-1-(3-acetoxy-2-acetoxymethyl-2-

- 5 methylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]piperidine-4-acetic acid, N-[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]piperidine-4-acetic acid ethyl ester,
- 10 N-[(3R,5S)-1-(3-acetoxy-2-acetoxymethyl-2-methylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]piperidine-4-acetic acid ethyl ester, (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-1,2,3,5-tetrahydro-3-[1H(or 3H)-tetrazol-5-yl]methyl-4,1-benzoxazepine-3-one,
- 15 (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2-hydroxymethyl-2-methylpropyl)-1,2,3,5-tetrahydro-3-[1H(or 3H)-tetrazol-5-yl]methyl-4,1-benzoxazepine-3-one, (3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-3-[1H(or 3H)-tetrazol-5-yl]methyl-4,1-benzoxazepine-3-one,
- 20 (3R,5S)-1-(3-acetoxy-2-acetoxymethyl-2-methylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-3-[1H(or 3H)-tetrazol-5-yl]methyl-4,1-benzoxazepine-3-one, (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-neopentyl-2-oxo-N-[2-(pyrrolidin-1-yl)ethyl]-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetamide, etc.
- 25

As salts of the compound (I), mention is made of pharmaceutically acceptable salts including inorganic salts such as hydrochloride, hydrobromide, sulfate, nitrate and phosphate, organic acid salts such as acetate, tartrate, citrate, fumarate, maleate, toluenesulfonate and methanesulfonate, metal salts such as sodium salt, potassium salt, calcium salt and aluminum salt, and basic salts such as triethylamine salt, guanidine salt, ammonium salt, hydrazine salt, quinine salt and cinchonine salt.

30

35

Hydrate and non-hydrate of compound (I) are also concluded in the scope of this invention.


In the compound represented by the formula (I) or salts thereof, asymmetric carbons exist at 3- and 5-positions, and trans-compounds, in which the substituent at 3-position and substituent at 5-position are faced to the reverse direction relative to the face of the 7-membered ring, is preferable. Especially, those in which the absolute configuration at 3-position is R-configuration and the absolute configuration at 5-position is S-configuration, are preferable.

While the compound represented by the above-mentioned formula (I) or salts thereof can be produced in accordance with, for example, methods disclosed in EPA567026, WO95/21834 [PCT application based on Japanese Patent Application H6(1994)-15531], EPA645377 [application based on Japanese Patent Application H6(1994)-229159] and EPA645378 [application based on Japanese Patent Application H6(1994)-229160], or methods analogous to them, they can be produced also by, for example, the following methods.

More specifically, the compound of the formula (I) or a salt thereof can be produced, as shown by, for example, the following formula, by subjecting a corresponding 3-carboxymethyl compound (I') to condensation with a compound represented by the formula



(R₂ and R₃ are defined above)




10

[wherein each symbol is of the same meaning as defined above].

The compound (I) or a salt thereof can be produced by subjecting the compound represented by the formula (I') to condensation with the compound represented by the formula

15




20 in a solvent, in the presence of a base when necessary, using a condensing agent. Examples of the solvent include hydrocarbons such as benzene, toluene, hexane and heptane, halogenic solvents such as dichloromethane, dichloroethane, chloroform and carbon tetrachloride, ethers such as ethyl ether,

25 tetrahydrofuran and dioxane, acetonitrile and dimethylformamide. As the base, mention is made of triethylamine, 4-dimethylaminopyridine, triethylenediamine and tetramethylethylenediamine. As

30 the condensing agent, mention is made of condensing agents employed for the synthesis of peptide, as exemplified by dicyclohexyl carbodiimide, diethyl cyanophosphate and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide. The compound

35 represented by the formula



is used in an amount ranging from 0.5 to 2 molar
5 equivalents, preferably from 1 to 1.2 molar equivalent,
relative to one mole of the compound shown by the
formula (I'), and the condensing agent is used in an
amount ranging from 0.5 to 5 molar equivalents,
preferably from 1 to 2 molar equivalents. The reaction
10 temperature ranges from 0 to 100 °C, preferably from 20
to 50 °C. The reaction time ranges from 0.5 to 24
hours, preferably from about 1 to about 5 hours.

The compound (I) or a salt thereof with X as
optionally substituted heterocyclic group having a
15 deprotonizable hydrogen atom, by X, or the carbamoyl
group substituted with the optionally substituted
heterocyclic group having a deprotonizable hydrogen
atom can be produced by converting the carboxyl group
in the carbamoyl group substituted with carboxyl group
20 or a substituent having carboxyl group, shown by X,
into carboxylic acid amido, subjecting the carboxylic
acid amido to dehydration to convert it further into
cyano group, then converting the cyano group into the
optionally substituted heterocyclic group having a
25 deprotonatable hydrogen atom.

The above-mentioned conversion of carboxylic acid
into carboxylic acid amido can be conducted in
accordance with a per se known method. For example, a
compound with carboxylic acid group is subjected to
30 condensation with ammonium or ammonium chloride, when
necessary in the presence of a base (e.g.
triethylamine, dimethylaminobenzene, pyridine,
potassium carbonate, sodium carbonate, potassium
hydrogencarbonate or sodium hydrogencarbonate), using a
35 condensing agent such as diethyl cyanophosphate or
dicyclohexyl carboxiimide. As the solvent to be

employed, mention is made of ethers such as diethyl ether, tetrahydrofuran or dioxane, halogen type solvents such as dichloromethane, chloroform or carbon tetrachloride, dimethylformamide and acetonitrile. In these solvents, relative to one mole of a compound having carboxyl group, 1 to 100, preferably about 1 to 5, molar equivalent of ammonia or ammonium chloride is used. The reaction temperature ranges from 0 to 100 °C, preferably from 0 to 50 °C, and the reaction time ranges from 0.1 to 24 hours, preferably from about 0.5 to about 5 hours.

For converting the carboxylic acid amido obtained thus above into cyano group, a compound having carboxylic acid amide is reacted with thionyl chloride in a solvent such as benzene, hexane, toluene or xylene to provide corresponding cyano compound.

The amount of thionyl chloride to be employed ranges, relative to 1 mole of the compound having carboxylic acid amido, from 1 to 10, preferably from 1 to 3, molar equivalents. The reaction temperature ranges from 50 to 200 °C, preferably from 70 to 150 °C. The reaction time ranges from 0.5 to 10 hours, preferably from about 0.5 to about 3 hours.


The above-mentioned conversion of cyano group into the optionally substituted heterocyclic group having a deprotonizable proton, e.g. tetrazole ring, can be performed by allowing a compound having cyano group to react with trimethylsilyl azide and dibutyltin (IV) oxide in a solvent such as benzene, hexane, toluene or xylene.

The amount of trimethylsilyl azide ranges, relative to 1 mole of the compound having cyano group, from 0.5 to 10, preferably from 1 to 3, molar equivalents, and the amount of dibutyltin (IV) oxide ranges from 0.01 to 3, preferably from about 0.05 to about 1, molar equivalents. The reaction temperature

ranges from 0 to 200 °C, preferably from 50 to 150 °C. The reaction time ranges from 10 to 48 hours, preferably from 15 to 30 hours. Furthermore, conversion into, for example, 2,5-dihydro-5-oxo-1,2,4-oxadiazole ring can be performed by allowing hydroxylamine to react with the compound having cyano group, then by further carbonylating the resultant compound. Hydroxylamine (1 to 10, preferably 1 to 3, equivalents relative to 1 mole of the compound having cyano group) is allowed to react with the compound having cyano group in a solvent as exemplified by an alcohol solvent such as methanol, ethanol and propanol, dimethylformamide or acetonitrile, in the presence of a base such as sodium hydrogencarbonate, potassium hydrogencarbonate or potassium carbonate, at a temperature ranging from 30 to 150 °C, preferably from 50 to 100 °C, for 1 to 24 hours, preferably about 5 to about 10 hours. For carbonylation of the compound thus obtained, carbodiimide or phosgene, for example, is employed for the carbonylating agent, and, as the solvent, for example, ether type solvents such as diethyl ether, tetrahydrophosgene or dioxane, halogen type solvents such as dichloromethane or chloroform, and ethyl acetate are employed. The amount of the carbonylating agent ranges from 1 to 10, preferably 1 to 3 molar equivalents. The reaction temperature ranges from 30 to 150 °C, preferably from 50 to 100 °C, and the reaction time ranges from 1 to 24, preferably from about 3 to about 100 hours.

In the above-described reaction, the compound, in which the moiety corresponding to X of the synthetic intermediate is an esterified carboxyl group or an optically active carboxyl group, can be obtained by, for example, the method disclosed in WO095/21834. More specifically, at first, the corresponding racemic compound is obtained, which is then allowed to react

with an optically active amino acid to form the amido bond, followed by subjecting the resultant compound to distillation, recrystallization and column chromatography to separate and purify the optically active isomer, and then, the amido bond is again cleaved to give a (3R,5S) compound. Alternatively, by the cleaved reaction step shown by the formula:



[wherein Piv stands for pivaloyl group, and other symbols are of the same meanings as defined above], enzymatic asymmetric hydrolysis is conducted to give an optically active isomer (S-configuration) of a benzyl alcohol derivative, then, using this optically active isomer as the starting material, in accordance with the method disclosed in EPA567026, to give the above-mentioned (3R,5S) of the compound (I') as defined above.

The compound represented by the formula (I) or a salt thereof in the present invention [hereinafter sometimes called the compound of the formula (I) or the compound (I)] is low in toxicity, has a squalene synthetase inhibiting activity and an activity of lowering the level of triglyceride, and, has an excellent activity of lowering the level of lipids, and is useful for the prophylaxis or therapy of hyperlipemia such as hypercholesteremia and hypertriglycerolemia of mammals (e.g. mouse, rat, rabbit, dog, cat, cow, pig and man), and also useful for the prophylaxis or therapy of renal diseases such as nephritis and nephropathy, arteriosclerosis, ischemic diseases, myocardial infarction, angina

pectoris, aneurysm, cerebral arteriosclerosis, peripheral arteriosclerosis, thrombosis, diabetes mellitus (e.g. insulin resistant diabetes), pancreatic disorders and re-stenosis after percutaneous
5 transluminal coronary angioplasty (PTCA).

The use of this invention is described in further detail as follows.

In view of the triglyceride-lowering activity, cholesterol-lowering activity and biological properties
10 of the compound of the formula (1), the compound is especially useful for the therapy and prophylaxis of hyperlipemia, especially hypertriglycerolemia, hyperlipoproteinemia and hypercholesterolemia, and, atherosclerotic diseases caused therefrom, and,
15 secondary diseases thereof, for example, coronary diseases, cerebral ischemia, intermittent claudication and gangrene.

For the therapy of these diseases, the compound of the general formula (1) can be used singly or in
20 combination with any other medicinal ingredients containing a lipid-level lowering agent or a cholesterol-level lowering agent. In this case, these compounds are administered, preferably, orally, and, upon necessity, they may be administered as agents for
25 rectal use in the form of suppository. Examples of medicinal agents which can be used in combination with the compound (I) include fibrates [e.g. chlorofibrate, benzafibrate and gemfibrozil], nicotinic acid, its derivatives and analogues [e.g. acipimox and probucol],
30 bile acid binding resins [e.g. cholestyramine and cholestypol], compounds inhibiting cholesterol absorption [e.g. sitosterol or neomycin], compounds controlling the biosynthesis of cholesterol [e.g. HMG-CoA reductase inhibiting agents such as lovastatin, simvastatin and pravastatin], and squalene epoxidase
35 inhibiting agents [e.g. NB-598 and analogous

compounds]. As further agents which can be used in combination with the compound (I), mention is made of, for example, oxidosqualene-lanosterolcyclases such as decalin derivatives, azadecalin derivatives and indane derivatives.

Additional, the compound of the general formula (I) is applicable to treatment of diseases related to hyperchylomicronemia, for example, acute pancreatitis. The mechanism of occurrence of pancreatitis has been considered that minute thrombus occurs in pancreatic blood capillary by the action of chylomicron or by strong topical irritation with the increase of free fatty acid produced by decomposition of triglyceride by pancreatic lipase due to hyperchylomicronemia. In view of the above, since the compound of the formula (I) of this invention has an activity of lowering the level of triglyceride, it can be used for the therapy of pancreatitis, and can be used for the therapy of pancreatitis singly or in combination with a known therapeutic method. For the therapy of this disease, the compound of the formula (I) can be administered orally or topically, or it can be used singly or in combination with a known active compound. As the agent which can be combined for this purpose, mention is made of, for example, aprotinin (trasyolol), gabexate mesylate (FOY), nafamostat mesilate (Futhan), citicoline (nicholin) and urinastatin (miraclide). And, for the purpose of removing pain, anticholinergic drugs, non-narcotic analgesics and narcotic drugs can also be used.

As further noticeable examples of diseases, to which the compound of the general formula (I) is applicable, mention is made of secondary hyperlipemia including, for example, diabetes mellitus, hypothyroidism, nephrotic syndrome or chronic renal failure. In many cases, these diseases cause

hyperlipemia and the latter aggravates these diseases, causing a so-called vicious circle. Taking its lipid-level lowering activity into consideration, the compound of the general formula (I) is useful for the therapy and for preventing the aggravation of these diseases. For this purpose, the compound of the general formula (I) can be administered singly or in combination with exemplary medicines set forth below.

Medicines for diabetes mellitus: kinedak, benfil, humulin, euglucon, glimicron, daonil, novorin, monotard, insulins, glucobay, dimelin, rastinon, bacilcon, deamiline S, iszilins;

Medicines for hypothyroidism: thyroid (thyreoid), levothyroxine sodium (thyradin S), liothyronine sodium (cylonine, cylomin);

Medicines for nephrotic syndrome: For the therapy using steroid as the first choice, use is made of, for example, prednisolone sodium succinate (predonine), prednisolone sodium succinate (predonine), methyl prednisolone sodium succinate (solu-medrol) and betamethasone (renderon). And, for anticoagulant therapy, use is made of antiplatelet medicines such as dipyridamole (persantine) and dilazep hydrochloride (comelian);

Medicines for chronic renal failure: A combination of diuretics [e.g. furosemide (lasix), bumetanide (lunetoron) and azosemide (diart)], hypotensive drugs (e.g. ACE inhibitors (enalapril maleate (renivace)) and Ca antagonists (Ca antagonistic drugs (maninhilone), α -receptor blocking agents is administered, preferably, orally.

Another possible use of the compound of the general formula (I) of this invention is to inhibit the formation of thrombus. In view of the fact that the triglyceride level in blood is an positive correlation with the blood coagulation factor VII and intake of ω -3

type fatty acid serves to lower the triglyceride level and, at the same time, the coagulation is inhibited, it has been considered that hypertriglycemia would promote the formation of thrombus. Since VLDL (very low
5 density lipoprotein) of the patients suffering from hyperlipemia increased more strongly the secretion of plasminogen activator inhibitor from vascular endothelial cells than that of the patients suffering from normal lipemia, it is considered that triglyceride
10 (hereinafter TG) acts to lower the fibrinolytic activity. Therefore, taking the TG lowering action, the compound of the general formula (I) can be effectively used for the prophylaxis and therapy of the formation of thrombus. The compound (I) can be
15 administered singly or in combination with any of the following exemplary known therapeutic agents, preferably orally.

Medicines for prophylaxis and therapy of thrombus formation: blood coagulation inhibitors [e.g. heparin
20 sodium, heparin calcium, warfarin calcium (warfarin)], thrombolytic agents [e.g. urokinase], antiplatelet agents [e.g. aspirin, sulfinpyrazolo(anturane), dipyridamole (persantine), acropidin (panaldin), cilostazol (pletaal)].

25 The compound (I) can be used orally or non-orally in the manner of injection, drip infusion, inhalation, rectal administration or topical administration, as it is or as a medicinal composition (e.g. powder, granule, tablet, pill, capsule, injection, syrup, emulsion,
30 elixir, suspension and solution). In other words, at least one species of the compounds of this invention can be used singly or in combination with a pharmaceutically acceptable carrier (e.g. adjuvant, excipient, forming aid and/or diluent).

35 These pharmaceutical compositions can be prepared by a conventional method. These compositions can be

prepared by usually mixing/kneading active components with an additive such as excipients, diluents and carriers. In the present specification, "non-oral administration" include subcutaneous injection, intravenous injection, intramuscular injection, intraperitoneal injection or drip infusion. Injectable compositions, for example, a sterile injectable aqueous suspension or an oily suspension, can be prepared by a known method in the relevant field using a suitable dispersing agent or a moistening agent. The sterile injectable composition may be a solution or a suspension injectable under sterile conditions in a non-toxic diluent or a solvent administrable non-orally, for example, an aqueous solution. As a vehicle or a solvent which can be employed, mention is made of, for example, water, a Ringer solution and an isotonic aqueous saline solution. Further, a sterile non-volatile oil can also be employed as a common solvent or a suspending solvent. For this purpose, any non-volatile oil and fatty acid can also be employed, including natural or synthetic or semi-synthetic fatty oil or fatty acid as well as natural or synthetic or semi-synthetic mono- or di- or triglycerides.

The suppository for rectal use can be prepared by mixing the drug with a suitable non-irritable excipient, e.g. cocoa butter or polyethylene glycol which is solid at normal temperatures, liquid at temperatures in intestinal tube, and melts and release the drug in rectum.

As the solid dosage form for oral administration, mention is made of, for example, powder, granule, tablet, pill and capsule as mentioned above. The composition of such dosage form as above can be prepared by mixing and/or kneading a compound as the active component with at least one species of additives as exemplified by sucrose, lactose, cellulose, mannitol

(D-mannitol), multitol, dextrin, starch (e.g. corn starch), microcrystalline cellulose, agar, alginates, chitins, chitosans, pectins, tragacanth gum, acacia, gelatins, collagens, casein, albumin, synthetic or semi-synthetic polymers or glycerides. These compositions may optionally contain further additives, like in usual cases, for example, an inert diluent, a lubricant such as stearic acid and magnesium, a preservative such as parabens and sorbins, an antioxidant such as ascorbic acid, α -tocopherol and cysteine, a disintegrant (e.g. floscaromelose sodium), a binder (e.g. hydroxypropyl cellulose), a thickening agent, a buffering agent, a sweetening agent, a flavoring agent and perfuming agent. Tablets and pills may optionally be prepared with enteric coating. As liquid preparations for oral administration, mention is made of, for example, a pharmaceutically acceptable emulsion, syrup, elixir, suspension and solution, and they may optionally contain an inert diluent such as water and, depending on necessity, an additive. These liquid compositions for oral administration can be prepared by a conventional method, for example, mixing the compound as the active component with an inert diluent and, upon necessity, any other additive.

25 The orally administrable compositions, while varying with the forms, are incorporated with usually 0.01 to 99 W%, preferably 0.1 to 90 W%, commonly 0.5 to 50% of the compound of this invention as the active component. The dose for a specific patient is

30 determined, while taking into consideration age, body weight, general health conditions, sex, diet, the time of administration, the method of administration, secretion rate, combination of drugs, conditions of the disease then the patient is receiving the therapy and

35 any other factors. A lipid level lowering agent such as a triglyceride level lowering agent comprising the

compound (I) of this invention is relatively low in toxicity and can be safely used. Although the daily dose varies depending on the conditions and body weight of the patient, kinds of the compound, administration routes and any other factors, a daily dosage per adult human (about 60 kg body weight) in the case of, for example, oral administration for the prophylaxis and therapy of hyperlipemia ranges from about 1 to 500 mg, preferably from about 10 to 200 mg, of the effective component [compound (I)], and, in the case of a non-orally administrable composition, the daily dose range from about 0.1 to 100 mg, preferably from about 1 to 50 mg, commonly from about 1 to 20 mg in terms of the effective component. Within this range, no toxicity is observed at all.


Best Mode of Carrying out the Invention

The following Working Examples, formulation examples and experimental examples are intended to illustrate the present invention in further detail and should by no means be construed as limiting the invention.

[Examples]

Working Example 1

Methyl ester of N-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]piperidine-4-carboxylic acid



To a solution of (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-

4,1-benzoxazepine-3-acetic acid (0.5 g) and 0.25 g of
piperidine-4-carboxylic acid methyl ester hydrochloride
in dimethylformamide (10 ml) were added, at room
temperature, diethylcyanophosphonate (0.28 g) and
5 triethylamine (0.38 ml), and the mixture was stirred
for one hour. To the mixture were added water (100 ml)
and ethyl acetate (100 ml). The organic layer was
washed with 1N HCl and a saturated aqueous solution of
sodium hydrogencarbonate, followed by drying over an
10 hydrous magnesium sulfate. The solvent was distilled
off, and the residue was purified by silica gel column
chromatography (eluents: hexane : ethyl acetate = 1:1
(v/v) to afford 0.62 g of a colorless crystalline
product, m.p. 124-126°C.

15 Elemental analysis for $C_{31}H_{39}ClN_2O_7 \cdot 0.3H_2O$:


Calcd. : C, 62.84; H, 6.74; N, 4.73

Found : C, 62.78; H, 6.69; N, 4.72













Working Example 2











20 By substantially the same procedure as in Example
1, compounds shown in [Table 1] were obtained.

[Table 1]



Compound No.	Y	m.p. (°C)
2-1		159-160
2-2		110-112
2-3		200-202
2-4		123-125
2-5		196-198
2-6		169-171
2-7		256-258
2-8		175-177
2-9		86-89

Compound No.	Y	m.p. (°C)
2-10		154-155
2-11		141-142
2-12		146-148
2-13		111-113
2-14		125-127
2-15		180-180.5
2-16		195-197
2-17		203-204
2-18		132-134
2-19		197-200
2-20		165-166
2-21		142-145

Compound No.	Y	m.p. (°C)
2-22		209-210
2-23		123-125
2-24		96-98
2-25		107-108
2-26		142-144
2-27		216-218
2-28		132-134
2-29		amorphous solid
2-30		amorphous solid
2-31		amorphous solid


Compound No	Y	m.p. (°C)
2-32		104-106
2-33		115-116
2-34		103-105
2-35		193-195
2-36		126-128
2-37		124-127
2-38		150-151

25

Working Example 3

N-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]piperidine-4-carboxylic acid

30



35

The compound (0.5 g) obtained in Example 1 was dissolved in a mixture of 1N aqueous solution of sodium hydroxide (4 ml), methanol (10 ml) and tetrahydrofuran (5 ml). The solution was stirred for one hour at room temperature, to which were added 1N HCl (50 ml) and ethyl acetate (100 ml). The organic layer was washed with water and dried over anhydrous magnesium sulfate. The solvent was removed, and the residue was recrystallized from hexane-diethyl ether to afford 0.47 g of colorless crystals, m.p. 145-147°C

Elemental analysis for $C_{30}H_{37}ClN_2O_7 \cdot 0.3H_2O$:


Calcd. : C, 62.29; H, 6.55; N, 4.84

Found : C, 62.20; H, 6.65; N, 4.83













Working Example 4











By subjecting the compound obtained in Example 2 to substantially the same procedure as in Example 3, compounds shown in [Table 2] were obtained.




[Table 2]



Compound No.	Y	m.p. (°C)
4-1		amorphous solid
4-2		137-140
4-3		214-217
4-4		132-136
4-5		136-144
4-6		157-160
4-7		160-170
4-8		137-139
4-9		152-155


Compound No.	Y	m.p. (°C)
4-10		145-150
4-11		107-110
4-12		134-136
4-13		135-140
4-14		147-150
4-15		134-136
4-16		140-142
4-17		137-140
4-18		228-230
4-19		156-159
4-20		163-166
4-21		165-167

Compound No.	Y	m.p. (°C)
4-22		145-147
4-23		amorphous solid
4-24		122-124
4-25		158-160
4-26		160-162
4-27		200-205
4-28		amorphous solid
4-29		129-132
4-30		87-92
4-31		162-164

Compound No.	Y	m.p. (°C)
4-32		amorphous solid
4-33		128-131
4-34		142-145

Working Example 5

3-[(3R,5S)-7-Chloro-5-(2,3-dimethoxyphenyl)-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetamino]propylamine hydrochloride



An ethanol solution of the compound (0.2 g) obtained in Example 6-31 and hydrazine·monohydrate (0.10 g) was stirred for one hour at 70°C. To the reaction mixture was added ethyl acetate (50 ml). The mixture was washed with water and dried, followed by distilling off the solvent. The residue was dissolved in acetate (50 ml), to which was added hydrogen chloride (4N solution in ethyl acetate) (0.1 ml). The solvent was distilled off, and the residue was recrystallized from ethanol-diethyl ether to afford 50 mg of colorless crystals, m.p. 158-163°C. Elemental analysis for $C_{27}H_{37}Cl_2N_3O_5 \cdot 1.7H_2O$:


Calcd. : C, 55.42; H, 6.92; N, 7.18

Found : C, 55.21; H, 6.90; N, 7.12













Working Example 6

- 5 Employing (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetic acid, substantially the same procedure as in Example 1 was conducted to obtain compounds shown in [Table 3].







[Table 3]



Compound No.	Y	m.p. (°C)
6-1		95-101
6-2		135-230 (decomp.)
6-3		101-105
6-4		270-283 (decomp.)
6-5		109-111
6-6		243-245
6-7		amorphous solid
6-8		133-135
6-9		164-165

Compound No.	Y	m.p. (°C)
6-10		99-103
6-11		96-98
6-12		143-145
6-13		136-140
6-14		119-122
6-15		119-121
6-16		106-109
6-17		amorphous solid
6-18		204-206
6-19		106-108
6-20		111-121
6-21		118-120


Compound No.	Y	m.p. (°C)
6-22		112-119
6-23		115-117
6-24		112-114
6-25		145-148
6-26		184-185
2-27		125-127
2-28		145-150
6-29		173-174
6-30		181-183
6-31		oil
6-32		90-95
6-33		118-120

Compound No.	Y	m.p. (°C)
6-34		147-148
6-35		118-121
6-36		97-100
6-37		227-228
6-38		amorphous solid
6-39		192-194

Working Example 7

(3R,5S)-7-Chloro-5-(2,3-dimethoxyphenyl)-1-neopentyl-1,2,3,5-tetrahydro-3-(1H(or 3H)-tetrazol-5-yl)methyl-4,1-benzoxazepin-2-one

30



(1) A dimethylformamide solution of (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-neopentyl-2-oxo-1,2,3,5-

tetrahydro-4,1-benzoxazepine-3-acetic acid (2.0 g), ammonium chloride (1.2 g) and triethylamine (1.0 ml) was cooled in ice bath. To the solution were added diethylcyanophosphonate (0.85 g) and triethylamine (0.5 ml). The mixture was stirred for further 20 minutes, to which was added ice-water, followed by extraction with ethyl acetate. The organic layer was washed with water, which was dried over anhydrous magnesium sulfate. The solvent was distilled off, and the residue was recrystallized from diethyl ether to give 1.0 g of (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetamide as colorless crystals, m.p. 170-172°C.

(2) The compound (3.2 g) obtained in (1) and thionyl chloride (1.8 ml) were suspended in toluene (40 ml). The suspension was stirred for one hour at temperatures ranging from 110 to 120°C. The solvent was removed. To the residue were added ethyl acetate (100 ml) and a saturated aqueous solution of sodium hydrogencarbonate (50 ml). The organic layer was dried over anhydrous sodium sulfate, then the solvent was distilled off. The residue was purified by silica gel column chromatography (eluents: hexane : ethyl acetate = 3:1 (v/v)) to give 1.7 g of (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-neopentyl-1,2,3,5-tetrahydro-3-cyanomethyl-4,1-benzoxazepin-2-one as colorless crystals, m.p. 193-194°C.

(3) To a solution of the compound (1.7 g) obtained in (2) in toluene (20 ml) were added trimethyl silyl azide (0.45 g) and dibutyltin (IV) oxide (30 mg). The mixture was stirred for 24 hours at temperatures ranging from 110 to 120°C. The reaction mixture was concentrated, to which was added diethyl ether (20 ml), followed by washing with an aqueous solution of sodium hydroxide. The aqueous layer was acidified with 1N HCl, which was then subjected to extraction with ethyl

acetate. The organic layer was washed with water, which was then dried over anhydrous sodium sulfate. The solvent was distilled off, and the residue was recrystallized from dichloromethane-hexane to give
5 colorless crystals, m.p. 148-150°C.

Elemental analysis for $C_{24}H_{28}ClN_3O_4 \cdot 0.5H_2O$:


Calcd. : C, 58.24; H, 5.91; N, 14.15

Found : C, 58.43; H, 6.18; N, 13.76

Working Example 8

10 (3R,5S)-7-Chloro-5-(2,3-dimethoxyphenyl)-1-neopentyl-3-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)methyl-1,2,3,5-tetrahydro-4,1-benzoxazepin-2-one

15



20 To ethanol (15 ml) were added the compound (0.5 g) obtained in Example 7-(2), hydroxylamine hydrochloride (0.25 g) and sodium carbonate (0.55 g). The mixture was heated for 8 hours under reflux. The reaction mixture was concentrated under reduced pressure, to
25 which were added ethyl acetate (20 ml) and water (20 ml). The organic layer was washed with water, which was then dried over anhydrous sodium sulfate. The solvent was distilled off. The residue (0.55 g), carbodiimidazole (0.5 g) and triethylamine (0.3 ml)
30 were dissolved in ethyl acetate (30 ml). The solution was heated for 6 hours under reflux. The reaction mixture was washed with water and dried. The solvent was distilled off. The residue was purified by silica gel column chromatography (eluent:
35 dichloromethane:methanol:H₂O = 250:5:0.5(v/v)) to give 0.44 g of colorless crystals, m.p. 130-133°C.

Elemental analysis for $C_{25}H_{28}ClN_3O_6$:


Calcd. : C, 59.82; H, 5.62; N, 8.37

Found : C, 59.57; H, 5.78; N, 7.97

Working Example 9

- 5 (3R,5S)-7-Chloro-5-(2,3-dimethoxyphenyl)-1-neopentyl-
1,2,3,5-tetrahydro-3-(tetrazol-5-yl)methyl-4,1-
benzoxazepin-2-one sodium salt

10



15

To a solution of the compound (0.6 g) obtained in
Example 7 in methanol (10 ml) was added 1N NaOH (1.02
ml), which was concentrated under reduced pressure.
The concentrate was dissolved in ethyl acetate (30 ml),
which was concentrated under reduced pressure to leave
a powdery residue. To the powdery residue was added
diethyl ether (20 ml), which was filtrated to collect
0.61 g of a white powdery product.

20

Elemental analysis for $C_{26}H_{27}ClN_5O_4Na \cdot H_2O$:

Calcd. : C, 54.81; H, 5.56; N, 13.31


25

Found : C, 54.59; H, 5.82; N, 13.03

Working Example 10

5-[2-[N-[(3R,5S)-7-Chloro-5-(2,3-dimethoxyphenyl)-1-
neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-
acetyl]piperidin-4-yl]]1H(or 3H)tetrazole

30



35

The compound (0.3 g) obtained in Example 6-29 was subjected to substantially the same procedure as in Example 7-(3) to give 0.25 g of colorless crystals, m.p. 185-187°C.

5 Elemental analysis for $C_{30}H_{37}ClN_6O_5 \cdot H_2O$:


Calcd. : C, 58.58; H, 6.39; N, 13.66

Found : C, 58.84; H, 6.15; N, 13.46

Working Example 11

(3R,5S)-7-Chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-1,2,3,5-tetrahydro-3-[1H (or 3H)-tetrazol-5-yl]methyl-4,1-benzoxazepin-2-one

15



20 (1) To a solution of (S)-4-chloro-2-[α-hydroxy-(2,3-dimethoxyphenyl)methyl]aniline (2.0 g) and sodium hydrogencarbonate (0.86 g) in ethyl acetate (20 ml) was added dropwise a solution of monoethyl ester of dimethyl malonic acid chloride (1.3 g) in ethyl acetate

25 (20 ml). The mixture was stirred for 3 hours under ice-cooling. To the solution was added water (30 ml), and the organic layer was dried over anhydrous sodium sulfate. The solvent was distilled off, and the residue was purified by silica gel column

30 chromatography to give (S)-2-[N-[2-(2,3-dimethoxy-α-hydroxybenzyl)-4-chlorophenyl]carbamoyl]-2,2-dimethylacetic acid ethyl ester (2.92 g) as a colorless oily compound.

$^1\text{H-NMR}(\text{CDCl}_3)$ δ : 1.22(3H,t,J=7.4Hz), 1.37(3H,s), 1.42(3H,s), 3.84(3H,s), 3.89(3H,s), 4.05-4.19(3H,m), 6.01(1H,s), 6.61(1H,dd,J=1.8,7.4Hz), 6.90-7.05(3H,m),

7.28(1H,dd,J=3.0,8.8Hz), 8.07(1H,d,J=8.4Hz),
9.49(1H,br)

(2) To a solution of the compound (2.83 g) obtained in
(1) in tetrahydrofuran (30 ml) was added, under ice-
cooling, lithium aluminum hydride (0.5 g). The mixture
was stirred for 3 hours at room temperature. To the
reaction mixture were added a 1N aqueous solution of
sodium hydroxide (13 ml) and water (50 ml), then
insolubles were filtered off. The filtrate was
extracted with ethyl acetate. The extract was washed
with water and dried, then the solvent was distilled
off. The residue was purified by silica gel column
chromatography (eluents: hexane:ethyl acetate = 1:1
(v/v)) to give (S)-[5-chloro-2-(2,2-dimethyl-3-
hydroxypropyl)aminophenyl](2,3-dimethoxyphenyl)methanol
(0.88 g) as a colorless oily compound.

¹H-NMR(CDCl₃) δ: 0.91(3H,s), 0.93(3H,s), 2.95(2H,s),
3.37(2H,s), 3.83(3H,s), 3.88(3H,s), 5.99(1H,s),
6.63(1H,d,J=8.8Hz), 6.77(1H,dd,J=1.6,7.6Hz),
6.90(1H,dd,J=1.6,7.6Hz), 7.03(1H,d,J=2.6Hz),
7.03(1H,t,J=7.6Hz), 7.13(1H,dd,J=2.6,8.8Hz)

(3) To a solution of the compound (0.88 g) obtained in
(2) in ethyl acetate (10 ml) was added sodium
hydrogencarbonate (0.39 g). To the mixture was added a
solution of monoethyl ester of fumaric acid chloride
(0.45 g) in ethyl acetate (10 ml), which was stirred
for 30 minutes at room temperature. The reaction
mixture was washed with water and dried, then the
solvent was distilled off. The residue was dissolved
in ethanol (10 ml), to which was added potassium
carbonate (0.70 g). The mixture was stirred overnight
at room temperature. To the reaction mixture was added
ethyl acetate (50 ml), which was washed with water and
dried. The solvent was distilled off, and the residue
was recrystallized from ethyl acetate - hexane to give
(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-

dimethyl-3-hydroxypropyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetic acid ethyl ester (0.57 g) as colorless crystals, m.p. 188-190°C.

5 (4) The compound (0.5 g) obtained in (3) was dissolved in a mixture of tetrahydrofuran (5 ml) and ethanol (3 ml). To the solution was added a 1N aqueous solution of sodium hydroxide (1 ml), which was stirred for 20 minutes at 60°C. To the reaction mixture was added water (50 ml), which was extracted with ethyl acetate.
10 The extract was dried, and the solvent was distilled off. The residue was recrystallized from ethyl acetate - hexane to give (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetic acid
15 (0.33 g) as colorless crystals, m.p. 199-202°C.

(5) To a solution of the compound (2 g) obtained in (4) and 3-aminopropionitrile (0.29 g) in dimethylformamide (20 ml) were added, at room temperature, diethyl cyanophosphonate (0.75 g) and
20 triethylamine (0.51 g). The mixture was stirred for 30 minutes, to which was added ethyl acetate ester (100 ml). The mixture was washed with water and dried. The solvent was then distilled off, and the residue was recrystallized from hexane to give 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]amino]propionitrile (2.25 g) as colorless
25 crystals, m.p. 118-121°C.

(6) The compound (2 g) obtained in (5) and acetic anhydride (0.39 g) were dissolved in pyridine (20 ml).
30 To the solution was added dimethylaminopyridine (0.1 g), and the mixture was stirred for 30 minutes at room temperature. The solvent was distilled off, and the residue was dissolved in ethyl acetate (100 ml). The
35 solution was washed with 1N HCl and water, followed by drying over anhydrous magnesium sulfate. The solvent

was distilled off to leave 3-[(3R,5S)-1-(3-acetyloxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]aminopropionitrile (2.2 g) as a colorless
5 amorphous solid product.

¹H-NMR(CDCl₃) δ: 0.95(3H,s), 1.01(3H,s), 2.03(3H,s),
2.55-2.71(2H,m), 2.92(1H,dd,J=8.0,14.4Hz), 3.41-
3.59(3H,m), 3.62(3H,s), 3.72(1H,d,J=11.2Hz),
3.86(1H,d,J=11.2Hz), 3.90(3H,s),
10 4.33(1H,dd,J=5.0,8.0Hz), 4.56(1H,d,J=14.2Hz),
6.26(1H,s), 6.50-6.60(1H,br), 6.64(1H,s), 6.97-
7.38(5H,m)

(7) A solution of the compound (2.2 g) obtained in
(6), triphenylphosphine (2.0 g), diethyl
15 azodicarboxylate (0.87 g) and triethylsilyl azide (1.3
g) in tetrahydrofuran (10 ml) was stirred for 2 hours
at 60°C. The reaction mixture was concentrated under
reduced pressure. The concentrate was purified by
silica gel column chromatography (elvents: hexane :
20 ethyl acetate = 1:1 (v/v)) to give (3R,5S)-7-chloro-3-
[1-(2-cyanoethyl)-1H-tetrazol-5-yl]methyl-5-(2,3-
dimethoxyphenyl)-1-(2,2-dimethyl-3-hydroxypropyl)-
1,2,3,5-tetrahydro-4,1-benzoxazepin-2-one as a
colorless oily compound. This compound was dissolved
25 in a mixture of methanol (10 ml) and tetrahydrofuran
(10 ml), to which was added a 1N aqueous solution of
sodium hydroxide (8 ml). The mixture was stirred for
one hour at 60°C. To the reaction mixture was added
water (50 ml), which was acidified with 1N HCl,
30 followed by extraction with ethyl acetate. The extract
was dried, and the solvent was distilled off. The
residue was recrystallized from ethyl acetate - hexane
to give 0.96 g of colorless crystals, m.p. 158-160°C.
Elemental analysis for C₂₄H₂₈ClN₅O₅:


35 Calcd. : C, 57.43; H, 5.62; N, 13.95
Found : C, 57.55; H, 5.58; N, 13.75

Working Example 12

The compound obtained in Example 11-(4) was subjected to substantially the same procedure as in Example 1 to afford compounds shown in [Table 4].

5 [Table 4]

10



Compound No.	Y	m.p. (°C)
12-1		115-116
12-2		121-124
12-3		133-135
12-4		134-137
12-5		160-161
12-6		116-119

15

20

25


30

Working Example 13

35 The compound obtained in Example 12 was subjected to substantially the same procedure as in Example 3 to

afford compounds shown in [Table 5].

[Table 5]




Compound No.	Y	m.p. (°C)
13-1		135-140
13-2		162-165
13-3		228-230
13-4		161-165
13-5		155-158

Working Example 14

N-Toluenesulfonyl-(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetylamide

5



To a solution of (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetic acid (0.5 g) and p-toluenesulfonamide (0.22 g) in dichloromethane were added 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide (0.27 g) and dimethylaminopyridine (20 mg). The mixture was stirred for 3 hours at room temperature, which was concentrated under reduced pressure. The concentrate was dissolved in ethyl acetate (100 ml). The solution was washed with water and dried, then the solvent was distilled off. The residue was purified by silica gel column chromatography (eluent: dichloromethane:methanol:water=200:10:1 (v/v)) to give 0.6 g of colorless crystals, m.p. 110-113°C.

Elemental analysis for $C_{31}H_{35}ClN_2O_7 \cdot H_2O$:


Calcd. : C, 58.81; H, 5.89; N, 4.42

Found : C, 58.73; H, 5.73; N, 4.62

25 Working Example 15

N-Methylsulfonyl-[N-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]piperidine]-4-acetylamide

30



35

In substantially the same procedure as in Example 14, N-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-

neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]piperidine-4-acetic acid (0.5 g) obtained in Example 4-2 and methansulfonamide (0.4 g) were used to give 0.3 g of colorless crystals, m.p. 158-160°C

5 Elemental analysis for $C_{32}H_{42}ClN_3O_8 \cdot 0.5H_2O$:


Calcd. : C, 57.09; H, 6.44; N, 6.24

Found : C, 56.85; H, 6.47; N, 6.09

Working Example 16

10 N-Methylsulfonyl-(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetylamine

15



20

(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetic acid and methansulfonamide were subjected to substantially the same procedure as in Example 14 to afford colorless crystals, m.p. 212°C.

Elemental analysis for $C_{25}H_{31}ClN_2O_7$:

25

Calcd. : C, 55.70; H, 5.80; N, 5.20

Found : C, 55.95; H, 6.01; N, 4.99


Working Example 17

30

By allowing (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetic acid to react respectively with orthomethylphenylsulfonamide, phenylsulfonamide, isopropylsulfonamide and ethylsulfonamide in substantially the same manner as in Working Example 14, the corresponding compounds as shown in Table 6 were produced.

35

[Table 6]



5

10

15


20

Compound No.	R	m.p. (°C)
17-1		amorphous solid
17-2		158-161
17-3		149-150
17-4	Et	135-140

Working Example 18

25 N-methylsulfonyl-[N-(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]piperidine]-4-carboxamide

30



35

Using the compound produced in Working Example 3 (0.5 g) and methanesulfonamide (0.1 g), substantially

the same procedure as in Working Example 14 was followed to give 0.41 g of a colorless crystalline product, m.p.187-189°C.


Elemental analysis for $C_{31}H_{40}ClN_3O_8S \cdot 1/2H_2O$:

5 Calcd. : C, 56.48; H, 6.27; N, 6.73

Found : C, 56.28; H, 6.41; N, 6.29

Working Example 19

(3R,5S)-N-methylsulfonyl-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetamide



Using the compound produced in Working Example 11- (4) (0.4 g) and methanesulfonamide (0.1 g), substantially the same procedure as in Working Example 14 was followed to give 0.075 g of a colorless crystalline product, m.p.221-223°C.


Elemental analysis for $C_{25}H_{31}ClN_2O_8S$:

25 Calcd. : C, 54.10; H, 5.63; N, 5.05

Found : C, 54.30; H, 5.69; N, 4.87

Working Example 20

(3R,5S)-N-methylsulfonyl-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2-hydroxymethyl-2-methylpropyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetamide



(1) To a solution of oxalyl chloride (2.2 ml) in dichloromethane (120 ml) was added dropwise, at -78°C, a solution of dimethyl sulfoxide (2.4 ml) in dichloromethane (20 ml). The mixture was stirred at -78°C for 10 minutes, to which was then added a solution of 5-(hydroxymethyl)-2,2,5-trimethyl-1,3-dioxane (2 g) in dichloromethane (40 ml). The mixture was stirred at -78°C for further 15 minutes. To this solution was added triethylamine (13.2 ml). The mixture was warmed up to 0°C, to which was added a saturated aqueous solution of ammonium chloride (40 ml). The organic layer was washed with water and dried over anhydrous sodium sulfate, followed by distilling off the solvent. The residue was purified by silica gel column chromatography [eluents: hexane-ethyl acetate (3:1)] to give 2 g of aldehyde of a colorless oily compound. To a methanol solution of this aldehyde (2 g) were added (S)-4-chloro-2-[α-hydroxy-(2,3-dimethoxyphenyl)methyl]-aniline (3.3 g) and acetic acid (0.75 g). The mixture was stirred at room temperature for 10 minutes, to which was then added sodium cyanoborohydride (0.8 g). The mixture was stirred at 60°C overnight, to which was added water, followed by extraction with ethyl acetate. The extract was sequentially washed with 1N aqueous solution of sodium hydroxide and water, which was dried over anhydrous sodium sulfate. The solvent was distilled off, and the residue was purified by silica gel column chromatography [eluents: hexane-ethyl

acetate (2:1)] to give 3.7 g of (S)-[2-(2,2,5-trimethyl-1,3-dioxan-5-ylmethyl)amino-5-chlorophenyl](2,3-dimethoxyphenyl)methanol as a colorless oily compound.

5 $^1\text{H-NMR}(\text{CDCl}_3)$ δ : 0.81(3H,s), 1.38-1.45(6H,m), 3.22(2H,s), 3.30-3.40(1H,br), 3.60(4H,s), 3.83(3H,s), 3.89(3H,s), 4.90-5.00(4H,br), 5.97(1H,s), 6.71-7.27(6H,m)

(2) To a solution of the compound produced in (1) (3.7 g) in ethyl acetate (40 ml) was added sodium hydrogencarbonate (1.78 g). To the mixture was added, at 0°C, monoethyl ester of fumaric acid chloride (1.41 g). The mixture was stirred at room temperature for 30 minutes. To the solution was added water. The organic layer was washed with water, which was then dried over anhydrous sodium sulfate, followed by distilling off the solvent. The residue (5.2 g) was dissolved in ethanol (100 ml), to which was added potassium carbonate (1.1 g). The mixture was stirred overnight at room temperature. To the reaction mixture was added water, which was extracted with ethyl acetate. The extract was dried over anhydrous sodium sulfate, then the solvent was distilled off. The residue was purified by silica gel column chromatography [eluents: hexane-ethyl acetate (2:1) to ethyl acetate] to afford 2.65 g of (3R,5S)-7-chloro-1-(2,2,5-trimethyl-1,3-dioxan-5-ylmethyl)-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetic acid ethyl ester (A) and 1.12 g of (3R,5S)-7-chloro-1-(3-hydroxy-2-hydroxymethyl-2-methylpropyl)-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetic acid ethyl ester (B), both as colorless amorphous solid products.

30 A: $^1\text{H-NMR}(\text{CDCl}_3)$ δ : 0.95(3H,s), 1.24(3H,t,J=7.0Hz), 1.36&1.39(each 3H,s), 2.77(1H,dd,J=5.8,16.4Hz), 3.04(1H,dd,J=7.8,16.4Hz), 3.29(1H,d,J=12.2Hz),

3.40(1H,d,J=12.2Hz), 3.58(3H,s), 3.68(2H,s),
3.89(3H,s), 4.07-4.19(3H,m), 4.40(1H,dd,J=5.8,7.8Hz),
4.48(1H,d,J=14.2Hz), 6.16(1H,s), 6.63(1H,d,J=1.8Hz),
6.95-7.45(6H,m)

5 B: ¹H-NMR(CDCl₃) δ: 0.62(3H,s), 1.25(3H,t,J=7.0Hz),
2.78(1H,dd,J=5.2,16.6Hz), 3.07(1H,dd,J=8.2,16.6Hz),
3.39-3.80(4H,m), 3.60(3H,s), 3.89(3H,s),
4.13(2H,dq,J=1.8,7.0Hz), 4.20-4.28(1H,m),
4.41(1H,dd,J=5.2,18.2Hz), 4.85(1H,d,J=14.6Hz),
10 6.12(1H,s), 6.63(1H,s), 6.89-7.39(6H,m)

(3) To an ethanol solution of the compound (A)
produced in (2) (2.25 g) was added a 1N aqueous
solution of sodium hydroxide (4.0 ml). The mixture was
stirred at 60°C for one hour, to which was added water,
15 followed by neutralization with 1N HCl. The reaction
mixture was extracted with ethyl acetate. The extract
was dried over anhydrous sodium sulfate, then the
solvent was distilled off to leave 2.3 g of (3R,5S)-7-
chloro-1-(2,2,5-trimethyl-1,3-dioxan-5-ylmethyl)-5-
20 (2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-be-
nzoxazepine-3-acetic acid as a colorless amorphous
solid product.

¹H-NMR(CDCl₃) δ: 0.95(3H,s), 1.35&1.39(each 3H,s),
2.84(1H,dd,J=5.4,16.4Hz), 3.08(1H,dd,J=7.8,16.4Hz),
25 3.28(1H,d,J=12.2Hz), 3.41(1H,d,J=12.2Hz), 3.58(3H,s),
3.69(2H,s), 3.89(3H,s), 4.16(1H,d,J=13.8Hz),
4.35(1H,dd,J=5.4,7.8Hz), 4.89(1H,d,J=13.8Hz),
6.16(1H,s), 6.65(1H,d,J=2.0Hz), 6.96-7.47(5H,m)


(4) To a solution of the compound produced in (3)
30 (0.15 g) in dimethylformamide (2 ml) were added
methanesulfonamide (29 mg), 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide·hydrochloride (65 mg)
and dimethylaminopyridine (10 mg). The mixture was
stirred overnight at room temperature, to which was
35 added ethyl acetate (50 ml). The mixture was washed
with water, followed by drying over anhydrous sodium

sulfate. The solvent was distilled off, and the residue was dissolved in acetone (2 ml). To the solution was added p-toluenesulfonic acid monohydrate (0.1 g). The mixture was stirred overnight at room temperature, to which was added ethyl acetate (50 ml). The mixture was washed with water, which was dried over anhydrous sodium sulfate, followed by distilling off the solvent. The residue was washed with a mixture of ethyl ether and hexane (1:1), which was filtrated to afford 40 mg of a colorless amorphous solid product.

$^1\text{H-NMR}(\text{CDCl}_3)$ δ : 0.63(3H,s), 2.85-2.92(2H,m), 3.28(3H,s), 3.25-3.70(5H,m), 3.59(3H,s), 3.89(3H,s), 4.43(1H,t,J=6.1Hz), 4.78(1H,d,J=14.2Hz), 8.16(1H,s), 6.67(1H,s), 6.95-7.40(6H,m)

Working Example 21

N-methylsulfonyl-[N-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]piperidine]-4-acetamide



Using the compound (0.5 g) produced in Working Example 13-1 and methanesulfonamide (0.1 g), substantially the same procedure as in Working Example 14 was followed to give 90 mg of colorless crystals, m.p.175-180°C.

Elemental analysis for $\text{C}_{32}\text{H}_{42}\text{ClN}_3\text{O}_9\text{S}$:

Calcd. : C, 56.50; H, 6.22; N, 6.18


Found : C, 56.70; H, 6.50; N, 5.90

Working Example 22

(3R,5S)-N-phosphonomethyl-7-chloro-5-(2,3-

dimethoxyphenyl)-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetamide

5



10 To a solution of the compound (1.0 g) produced in Working Example 2-38 in dichloromethane (5 ml) was added trimethylsilyl bromide (0.38 g). The mixture was stirred overnight at room temperature, to which was added ethyl acetate. The mixture was washed with a
15 0.5N aqueous solution of sodium hydroxide, a saturated aqueous solution of ammonium chloride and water, followed by drying over anhydrous sodium sulfate. The solvent was distilled off, and the residue was recrystallized from a mixture of ethanol and diethyl
20 ether (1:10) to afford 0.41 g of colorless crystals, m.p. 152-155°C

Elemental analysis for $C_{25}H_{32}ClN_2O_8P \cdot 1.7H_2O$:


Calcd. : C, 51.28; H, 6.09; N, 4.78

Found : C, 51.20; H, 6.11; N, 4.77

25 Working Example 23

N-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]-4-phosphonomethylpiperidine

30



35

Using the compound produced in Working Example 2-

37 (2 g), substantially the same procedure as in Working Example 22 was followed to afford 1 g of colorless crystals, m.p.174-175°C.


Elemental analysis for $C_{30}H_{41}ClN_2O_8P$:

5 Calcd. : C, 56.12; H, 6.75; N, 4.36

Found : C, 55.95; H, 6.58; N, 4.05

Working Example 24

5-[[N-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]piperidin-4-yl]methyl]1H(or 3H)-tetrazole



(1) To a solution of the compound produced in Working Example 4-2 (1.5 g) and ammonium chloride (0.7 g) in dimethylformamide (12 ml) were added, at 0°C, triethylamine (2.0 ml) and diethyl cyanophosphonate (0.5 g). The mixture was stirred for 40 minutes, to which was added water. The mixture was extracted with ethyl acetate. The extract solution was washed with water and dried over anhydrous sodium sulfate, followed by distilling off the solvent. The residue was recrystallized from hexane-ethyl acetate to afford 1.3 g of an amide compound, m.p.189-190°C.

(2) To a suspension of the compound produced in (1) (1.0 g) in toluene (20 ml) was added thionyl chloride (1 ml). The mixture was stirred at 90°C for 30 minutes. To the reaction mixture was added a saturated aqueous solution of sodium hydrogen carbonate. The mixture was extracted with ethyl acetate. The organic layer was dried, then the solvent was distilled off. The residue was purified by silica gel column

chromatography [eluents: hexane-ethyl acetate-methanol (15:10:1)] to give 0.69 g of colorless crystals, m.p.150-152°C.

(3) Using the compound produced in (2) (0.4 g), trimethylsilyl azide (0.16 g) and dibutyltin(IV) oxide (20 mg), substantially the same procedure as in Working Example 7-(3) was followed to afford 0.37 g of colorless crystals, m.p.168-170°C.


Elemental analysis for $C_{31}H_{39}ClN_6O_5 \cdot H_2O$:

Calcd. : C, 59.18; H, 6.58; N, 13.36

Found : C, 59.16; H, 6.43; N, 13.03

Working Example 25

5-[2-[N-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]piperidin-4-yl]ethyl]1H(or 3H)-tetrazole



20

The compound produced in Working Example 4-34 (0.3 g) was subjected to substantially the same procedure as in Working Example 24 to afford 0.25 g of colorless crystals, m.p.155-158°C.


Elemental analysis for $C_{32}H_{41}ClN_6O_5 \cdot H_2O$:

Calcd. : C, 59.76; H, 6.74; N, 13.07

Found : C, 59.91; H, 6.75; N, 12.87

Working Example 26

(3R,5S)-N-bis(ethoxy)phosphinylmethyl-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetamide



Using the compound produced in Working Example 11-
(4) (1.0 g) and diethyl aminomethylphosphonate (0.38 g), substantially the same procedure as in Working Example 1 was followed to afford 1.24 g of colorless crystals, m.p.138-140°C.


Elemental analysis for $C_{29}H_{40}ClN_2O_9P$:

Calcd. : C, 55.55; H, 6.43; N, 4.47

Found : C, 55.25; H, 6.47; N, 4.44

Working Example 27

(3R,5S)-N-phosphonomethyl-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetamide




The compound produced in Working Example 26 (0.3 g) was subjected to substantially the same procedure as in Working Example 22 to afford 0.26 g of an amorphous solid compound.

1H -NMR(CD_3OD) δ : 0.84(3H,s), 0.93(3H,s), 2.75-2.82(2H,m), 3.20(1H,d,J=11.4Hz), 3.40-3.70(3H,m), 3.58(3H,s), 3.89(3H,s), 4.35-4.46(2H,m), 6.18(1H,s), 6.53(1H,d,J=2.2Hz), 7.08-7.61(5H,m)

Working Example 28

Bispivaloyloxymethyl N-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]-4-bis(pivaloyloxymethyl)phosphinylmethylpiperidine




To a solution of the compound produced in Working Example 23 (0.15 g) and potassium hydroxide (28.2 mg) in water (1.5 ml) was added a solution of silver nitrate (102 mg). The mixture was stirred for 15 minutes, then resulting insolubles were collected by filtration, washed with water and diethyl ether, followed by drying under reduced pressure. The solid matter thus obtained was suspended in dichloromethane (2 ml). To the suspension was added Molecular Sieves (3A) (200 mg), and the mixture was stirred for 40 minutes. To the reaction mixture were added anisole (0.1 g) and pivaloylmethyl iodide (0.27 g), which was stirred at room temperature for 40 minutes, followed by filtering off insolubles. To the filtrate was added ethyl acetate (50 ml). The mixture was washed with water and dried, followed by distilling off the solvent. The residue was purified by silica gel column chromatography [eluents: hexane-ethyl acetate (1:1)] to afford 56 mg of a colorless amorphous solid product.

$^1\text{H-NMR}(\text{CDCl}_3)$ δ : 0.94(9H,s), 1.23(18H,s), 1.50-1.95(7H,m), 2.54-2.75(2H,m), 2.97-3.18(2H,m), 3.37(1H,d,J=14.4Hz), 3.62(3H,s), 3.89(3H,s), 3.90-4.00(1H,m), 4.48-4.54(3H,m), 5.64(2H,s), 5.70(2H,s), 6.27(1H,s), 6.59(1H,s), 6.95(1H,s), 6.95-7.33(5H,m)

Working Example 29

N-[(3R,5S)-7-chloro-1-(2,2,5-trimethyl-1,3-dioxan-5-ylmethyl)-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]piperidine-4-acetic acid ethyl ester




Using the compound produced in Working Example 20-(3) (2 g) and piperidine-4-acetic acid ethyl ester hydrochloride (0.7 g), substantially the same procedure as in Working Example 1 was followed to afford 2.4 g of a colorless amorphous solid product.

¹H-NMR(CDCl₃) δ: 0.96(3H,s), 1.25(3H,t,J=7.2Hz), 1.36&1.39(each 3H,s), 1.65-1.82(4H,m), 1.95-2.08(1H,m), 2.18-2.26(2H,m), 2.49-2.63(1H,m), 2.73(1H,dd,J=4.8,15.8Hz), 2.92-3.06(1H,m), 3.12(1H,dd,J=8.2,15.8Hz), 3.31(1H,d,J=12.0Hz), 3.10(1H,d,J=12.0Hz), 3.58(3H,s), 3.65(1H,d,J=11.8Hz), 3.73(1H,d,J=11.8Hz), 3.89(3H,s), 3.94-3.99(1H,m), 4.04-4.18(3H,m), 4.46-4.56(3H,m), 6.16(1H,s), 6.60-6.62(1H,m), 6.95-7.46(5H,m)

Working Example 30

N-[(3R,5S)-7-chloro-1-(3-hydroxy-2-hydroxymethyl-2-methylpropyl)-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]piperidine-4-acetic acid ethyl ester




To a solution of the compound produced in Working
 Example 29 (2.0 g) in acetone (20 ml) were added p-
 toluenesulfonic acid monohydrate (35 mg) and water (2
 ml). The mixture was stirred at 50°C for 6 hours. To
 the reaction mixture was added ethyl acetate (50 ml).
 The mixture was washed with a 1N aqueous solution of
 sodium hydroxide and water, followed by drying over
 anhydrous sodium sulfate. The solvent was distilled
 off to leave 1.62 g of a colorless amorphous solid
 product.

¹H-NMR(CDCl₃) δ: 0.62(3H,s), 1.00-1.34(2H,m),
 1.26(3H,t,J=7.4Hz), 1.70-1.81(2H,m), 1.95-2.08(1H,m),
 2.19-2.28(2H,m), 2.51-2.78(2H,m), 3.01-3.08(1H,m),
 3.17(1H,dd,J=9.0,15.2Hz), 3.40-3.74(5H,m), 3.60(3H,s),
 3.89(3H,s), 3.89-3.94(1H,m), 4.13(2H,q,J=7.4Hz), 4.48-
 4.54(2H,m), 4.83(1H,d,J=14.6Hz), 6.13(1H,s),
 6.61(1H,d,J=1.8Hz), 6.97-7.44(5H,m)

Working Example 31

N-[(3R,5S)-7-chloro-1-(3-hydroxy-2-hydroxymethyl-2-
 methylpropyl)-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-
 tetrahydro-4,1-benzoxazepine-3-acetyl]piperidine-4-
 acetic acid




To an ethanol solution of the compound produced in Working Example 30 was added a 1N aqueous solution of sodium hydroxide. The mixture was stirred at 60°C for 2 hours. To the reaction mixture were added water (100 ml) and ethyl acetate (50 ml), which was acidified with 1N HCl. The organic layer was washed with water and dried over anhydrous sodium sulfate. The solvent was distilled off to leave 0.94 g of a colorless amorphous solid product.

¹H-NMR(CDCl₃) δ: 0.63(3H,s), 1.05-1.36(2H,m), 1.70-1.85(2H,m), 1.92-2.05(1H,m), 2.23-2.32(2H,m), 2.51-2.80(2H,m), 2.96-3.23(2H,m), 3.44-3.70(5H,m), 3.60(3H,s), 3.89(3H,s), 3.91-4.00(1H,m), 4.48-4.54(2H,m), 4.78(1H,d,J=15.2Hz), 6.12(1H,s), 6.61(1H,s), 6.97-7.39(5H,m)

Working Example 32

N-[(3R,5S)-1-(3-acetoxy-2-acetoxymethyl-2-methylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]piperidine-4-acetic acid ethyl ester




To a solution of the compound produced in Working Example 30 (0.5 g) in pyridine (5 ml) were added acetic anhydride (0.20 g) and dimethylaminopyridine (10 mg). The mixture was stirred at room temperature for 30 minutes. To the reaction mixture was added ethyl acetate (50 ml). The mixture was washed with 1N HCl and water, which was then dried, followed by distilling off the solvent. The residue was purified by silica gel column chromatography (eluents: ethyl acetate) to afford 0.50 g of a colorless amorphous solid product.

¹H-NMR(CDCl₃) δ: 1.02(3H,s), 1.00-1.40(2H,m), 1.25&1.26(total 3H, each t, J=7.2Hz), 1.60-1.80(2H,m), 1.92-2.05(1H,m), 2.00(3H,s), 2.03(3H,s), 2.16-2.26(2H,m), 2.46-2.65(1H,m), 2.67-2.77(1H,m), 2.99-3.19(2H,m), 3.60(3H,s), 3.64-4.19(6H,m), 3.89(3H,s), 4.44-4.54(2H,m), 4.67(1H,d,J=14.6Hz), 6.23(1H,s), 6.65(1H,s), 6.96-7.34(5H,m)

Working Example 33

N-[(3R,5S)-1-(3-acetoxy-2-acetoxymethyl-2-methylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]piperidine-4-acetic acid

25




30 Using the compound produced in Working Example 31, substantially the same procedure as in Working Example 32 was followed to afford 0.28 g of a colorless amorphous solid product.

¹H-NMR(CDCl₃) δ: 0.95-1.36(2H,m), 1.03(3H,s), 1.71-1.83(2H,m), 1.93-2.07(1H,m), 2.00(3H,s), 2.05(3H,s), 2.23-2.33(2H,m), 2.48-2.63(1H,m), 2.65-2.78(1H,m),

3.00-3.18(2H,m), 3.60(3H,s), 3.65-4.14(6H,m),
3.89(3H,s), 4.46-4.56(2H,m), 4.66(1H,d,J=14.8Hz),
6.24(1H,s), 6.64(1H,s), 6.96-7.34(5H,m)

Working Example 34

5 (3R,5S)-N-methylsulfonyl-1-(3-acetoxy-2-acetoxymethyl-
2-methylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-
1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetamide




15

Using the compound produced in Working Example 20
(0.1 g), acetic anhydride (39 mg) and
dimethylaminopyridine (5 mg), substantially the same
procedure as in Working Example 32 was followed to
20 afford 70 mg of a colorless amorphous solid product.

¹H-NMR(CDCl₃) δ: 1.00(3H,s), 2.00&2.02(each 3H,s),
2.85(1H,dd,J=5.4,15.4Hz), 2.98(1H,dd,J=7.2,15.4Hz),
3.26(3H,s), 3.61(3H,s), 3.70(1H,d,J=14.2Hz),
3.84(1H,d,J=11.4Hz), 3.89(3H,s), 3.94-3.99(2H,m),
25 4.11(1H,d,J=11.4Hz), 4.40(1H,d,J=6.2Hz),
4.46(1H,d,J=14.2Hz), 6.28(1H,s), 6.69(1H,d,J=1.6Hz),
6.97-7.43(5H,m)

Working Example 35

30 N-[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-
(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-
benzoxazepine-3-acetyl]piperidine-4-acetic acid ethyl
ester



5


Using the compound produced in Working Example 12-1 (0.5 g), substantially the same procedure as in
 10 Working Example 32 was followed to afford 0.35 g of a colorless amorphous solid product.

¹H-NMR(CDCl₃) δ: 0.93(3H,s), 1.02(3H,s), 1.26(3H,t), 2.02(3H,s), 3.61(3H,s), 3.89(3H,s), 4.14(2H,q), 4.5(3H,m), 6.26(1H,s), 6.62(1H,s), 6.9-7.4(5H,m)

15 Working Example 36

N-[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]piperidine-4-acetic acid

20



25

Using the compound produced in Working Example 13-1 (0.37 g), substantially the same procedure as in
 Working Example 32 was followed to afford 0.35 g of a colorless crystalline product, m.p.194-196°C.

30 Elemental analysis for C₃₃H₄₁ClN₂O₉:

Calcd. : C, 61.44; H, 6.41; N, 4.34


Found : C, 61.23; H, 6.18; N, 4.39

Working Example 37

N-[(3R,5S)-7-chloro-1-(3-hydroxy-2-hydroxymethyl-2-methylpropyl)-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]-4-

35


hydroxypiperidine-4-acetic acid methyl ester



- 5
- 10 (1) To a solution of (3R,5S)-7-chloro-1-(3-hydroxy-2-hydroxymethyl-2-methylpropyl)-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetic acid ethyl ester (1.0 g) in ethanol (10 ml) was added a 1N aqueous solution of sodium hydroxide. The mixture
- 15 was stirred at 60°C for one hour. To the reaction mixture was added water, which was neutralized with 1N HCl, followed by subjecting to extraction with ethyl acetate. The extract solution was dried over anhydrous sodium sulfate. The solvent was distilled off, and the
- 20 residue was recrystallized from a mixture of ethyl acetate and hexane to afford 0.38 g of (3R,5S)-7-chloro-1-(3-hydroxy-2-hydroxymethyl-2-methylpropyl)-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetic acid, m.p.208-210°C.
- 25 (2) Using the compound produced in (1) (0.25 g) and 4-hydroxypiperidine-4-acetic acid methyl ester hydrochloride (0.105 g), substantially the same procedure as in Working Example 1 was followed to afford 0.125 g of a colorless amorphous solid product.
- 30 ¹H-NMR(CDCl₃) δ: 1.35-1.84(6H,m), 2.47(2H,d), 2.65-2.85(1H,m), 2.95-3.28(2H,m), 3.35-3.78(7H,m), 3.62(3H,s), 3.73(3H,s), 3.90(3H,s), 4.22-4.40(2H,m), 4.52(1H,dd), 4.84(1H,dd), 6.13(1H,d), 6.62(1H,m), 6.95-7.43(5H,m)
- 35 Working Example 38
(3R,5S)-7-Chloro-1-(3-hydroxy-2-hydroxymethyl-2-

methylpropyl)-1,2,3,5-tetrahydro-5-(2,3-dimethoxyphenyl)-3-(1H(or 3H)-tetrazol-5-yl)methyl-4,1-benzoxazepin-2-one

5



10

(1) To a solution of the compound produced in Working Example 20-(3) (0.5 g), ammonium chloride (0.25 g) and triethylamine (0.17 g) in dimethylformamide (5 ml) were added diethyl cyanophosphonate (0.21 g) and triethylamine (0.17 g). The mixture was stirred at room temperature for 30 minutes, to which was added ethyl acetate (50 ml). The mixture was washed with water, which was then dried over anhydrous sodium sulfate, followed by distilling off the solvent. The residue was purified by silica gel column chromatography (eluents: ethyl acetate) to give 0.52 g of an amide compound as amorphous solid.

20

(2) To a solution of dimethylformamide (41 mg) in acetonitrile (1.5 ml) was added oxalyl chloride (65 mg) at 0°C. The mixture was stirred for 10 minutes, to which were added a solution of the compound produced in (1) (0.25 g) in acetonitrile (1.5 ml) and pyridine (82 mg). The mixture was stirred at 0°C for 10 minutes. To the reaction mixture was added ethyl acetate (50 ml). The mixture was washed with water and dried over anhydrous sodium sulfate, followed by distilling off the solvent. The residue was purified by silica gel column chromatography [eluents: hexane - ethyl acetate (2:1)] to give 0.31 g of a nitrile compound.

30

(3) A solution of the compound produced in (2) (1.0 g) in toluene (15 ml) was subjected to substantially the

35

same procedure as in Working Example 7-(3), using trimethylsilyl azide (0.43 g) and dibutyltin (IV) oxide (45 mg) to give (3R,5S)-7-chloro-1-(2,2,5-trimethyl-1,3-dioxan-5-ylmethyl)-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-3-(tetrazol-5-yl)methyl-4,1-benzoxazepin-2-one (1.03 g) as a colorless amorphous solid product.


(4) To a solution of the compound produced in (3) (1.0 g) in acetone (10 ml) were added p-toluenesulfonic acid monohydrate (50 mg) and water (1 ml). The mixture was stirred at 60°C overnight. To the reaction mixture was added water (50 ml), which was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate. The solvent was distilled off, and the residue was purified by silica gel column

chromatography [eluents: ethyl acetate - methanol (20:1)] to give 0.87 g of a colorless amorphous solid product.

¹H-NMR(CDCl₃) δ: 0.69(3H,s), 3.45(1H,dd,J=4.4, 14.4Hz), 3.56-3.75(5H,m), 3.62(3H,s), 3.90(3H,s), 4.29(1H,dd,J=4.4, 8.8Hz), 4.63(1H,d,J=15.2Hz), 6.18(1H,s), 6.67(1H,d,J=2.2Hz), 7.05-7.43(5H,m)

Working Example 39

(3R,5S)-1-(3-Acetoxy-2-acetoxymethyl-2-methylpropyl)-7-chloro-1,2,3,5-tetrahydro-5-(2,3-dimethoxyphenyl)-3-(1H (or 3H)-tetrazol-5-yl)-4,1-benzoxazepin-2-one




(40 mg). The mixture was stirred at room temperature for 30 minutes, to which was added ethyl acetate (50 ml). The mixture was washed with 1N HCl and water, which was then dried over anhydrous sodium sulfate, followed by distilling off the solvent. The residue was washed with ethyl ether - hexane (1:1), which was filtrated to collect 0.80 g of a colorless amorphous solid product.

¹H-NMR(CDCl₃) δ: 0.98(3H,s), 2.03,2.04(each 3H,s), 3.40(1H,dd,J=5.1, 15.8Hz), 3.55-3.67(2H,m), 3.65(3H,s), 3.82-3.91(2H,m), 3.89(3H,s), 4.04(1H,d,J=11.6Hz), 4.18(1H,d,J=11.2Hz), 4.30(1H,dd,J=5.2,6.6Hz), 4.66(1H,d,J=14.6Hz), 6.27(1H,s), 6.69(1H,d,J=2.2Hz), 6.95-7.42(5H,m)

Working Example 40

(3R,5S)-N-[2-(Pyrrolidin-1-yl)ethyl]-7-chloro-1-(3-hydroxy-2-hydroxymethyl-3-methylpropyl)-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetamide



(1) To a solution of the compound produced in Working Example 20-(3) (0.5 g) and diethyl cyanophosphonate (54 mg) in dimethylformamide (1.5 ml) was added 1-(2-aminoethyl)pyrrolidine (0.16 g). The mixture was stirred at room temperature for 30 minutes, to which was added ethyl acetate (50 ml). The mixture was washed with water and dried, followed by distilling off the solvent. The residue was purified by silica gel column chromatography [eluents: ethyl acetate - methanol-triethylamine (10:1:0.1) to give (3R,5S)-N-[2-

(pyridin-1-yl)ethyl]-7-chloro-1-(2,2,5-trimethyl-1,3-dioxan-5-ylmethyl)-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetamide (0.19 g) as a colorless amorphous solid product.


5 (2) To a solution of the compound produced in (1) (0.19 g) in tetrahydrofuran (2 ml) was added conc. HCl (1 ml). The mixture was stirred at 60°C for 30 minutes, to which was added water (50 ml), followed by neutralizing with 1N NaOH. The resultant was extracted
10 with ethyl acetate, washed with water and dried, followed by distilling off the solvent. The residue was purified silica gel column chromatography (eluents: ethyl acetate - methanol-triethylamine (2:1:0.1) to give 97 mg of a colorless amorphous solid product.

15 ¹H-NMR(CDCl₃) δ: 0.62(3H,s), 1.75-1.80(4H,m), 2.50-2.72(7H,m), 2.87(1H,dd,J=7.0,14.2Hz), 3.31-3.76(7H,m), 3.59(3H,s), 3.89(3H,s), 4.45(1H,t),J=6.4Hz), 4.82(1H,d,J=15.0Hz), 6.12(1H,s), 6.35-6.50(1H,br), 6.62(1H,s), 6.99-7.37(5H,m)

20 Working Example 41

(3R,5S)-N-Methylsulfonyl-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetamide

25



30

The compound produced in Working Example 19 (1.2 g) was subjected to substantially the same procedure as in Working Example 39 to give 1.01 g of a colorless
35 crystalline product, m.p.108-112°C.


Elemental Analysis for C₂₇H₃₃ClN₂O₉S·1.5H₂O:

Calcd.: C, 51.96; H, 5.81; N, 4.49

Found : C, 52.01; H, 5.82; N, 4.30

Working Example 42

(3R,5S)-1-(3-Acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-3-[1H(or 3H)tetrazol-5-yl]methyl-4,1-benzoxazepin-2-one



The compound produced in Working Example 11 (80 mg) was subjected to substantially the same procedure as in Working Example 39 to give 25 mg of a colorless amorphous solid product.

¹H-NMR(CDCl₃) δ: 0.97(3H,s), 0.99(3H,s), 2.05(3H,s), 3.3-3.8(4H,m), 3.65(3H,s), 3.89(3H,s), 4.05(1H,d), 4.28(1H,dd), 4.62(1H,d), 6.27(1H,s), 6.68(1H,d), 6.9-7.4(5H,m)

Formulation Examples

A therapeutic agent of hyperlipemia containing, as its effective component, the compound (1) or a salt thereof of this invention can be formulated in accordance with, for example, the following prescriptions.

1. Capsules

(1) N-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]piperidine-4-acetic acid	10 mg
(2) Lactose	90 mg
(3) Microcrystalline cellulose	70 mg
(4) Magnesium stearate	10 mg
1 capsule	180 mg

(1), (2) and (3) and one half of (4) were blended and the mixture was granulated, to which was added the balance of (4). The mixture was filled in a gelatin capsule.

5 2. Tablets

5	(1) N-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]piperidine-4-acetic acid	10 mg
	(2) Lactose	35 mg
10	(3) Corn starch	150 mg
	(4) Microcrystalline cellulose	30 mg
	(5) Magnesium stearate	5 mg
	One tablet	230 mg

15 (1), (2), (3), two third of (4) and one half of (5) were blended and the mixture was granulated, to which were added the balance of (4) and (5). The mixture was subjected to compression-molding to provide tablets.

3. Injections

20	(1) N-[(3R,5S)-7-Chloro-5-(2,3-dimethoxyphenyl)-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]piperidine-4-acetic acid	10 mg
	(2) Inositol	100 mg
	(3) Benzyl alcohol	20 mg
25	One ampoule	130 mg

(1), (2) and (3) were dissolved in distilled water for injection to make the whole volume 2 ml, which was put in an ampoule, and the ampoule was sealed. All the processes were conducted under sterilized conditions.

30 Experimental Example 1

Squalene Synthetase Inhibitory Activity

Assay Method

The squalene synthetase inhibitory activity was assayed as follows with the enzyme solutions prepared in accordance with the method described below.

More specifically, an enzyme solution (protein

content 0.8 μ g) prepared in accordance with the method described below was added to a solution (total volume 50 μ l)) containing 5 μ M [1- 3 H] farnesyl pyrophosphate (specific activity 25 μ Ci/mole), 1 mM NADPH
5 (nicotinamide adenine dinucleotide phosphate of reduced type), 5 mM MgCl_2 , 6 mM glutathione, a 100 mM buffer solution of potassium phosphate (pH 7.4) and a test drug (used as an aqueous solution or a DMSO solution), then the reaction was allowed to proceed at 37°C for 45
10 minutes. To the reaction mixture was added 150 μ l of a mixture of chloroform and methanol (1:2) to suspend the reaction, followed by adding 50 μ l of chloroform and 50 μ l of a 3N solution of sodium hydroxide. 50 μ l of the chloroform layer (lower layer) containing the reaction
15 mixture having squalene as the principal component and 3 ml of toluene-based liquid scintillator were mixed, and its radioactivity was determined by means of a liquid scintillation counter.

The squalene synthetase inhibitory activity was
20 expressed in terms of the concentration inhibiting by 50% the radioactivity taken into the chloroform layer (IC_{50} , molar concentration (M)), as shown in Table 7.
Preparation of human-derived enzyme

Human hepatic carcinoma cells HepG2 (about 1×10^9
25 cells) obtained by incubation on a Dulbecco-modified Eagle's medium (37°C in the presence of 5% CO_2) containing 10% fetal bovine serum were suspended in 10 ml of an ice-cooled buffer solution [100 mM potassium phosphate buffer (pH 7.4), 30 mM nicotinamide and 2.5
30 mM MgCl_2]. The cells were crashed by means of ultrasonication (for 30 seconds, twice). The sonicate thus obtained was subjected to centrifugation for 20 minutes (4°C) with 10000 x g. The supernatant layer was subjected to further centrifugation for 90 minutes
35 (4°C) with 105000 x g. The sediment was then suspended in an ice-cooled 100 mM potassium phosphate buffer (pH

7.4), which was again subjected to centrifugation for 90 minutes (4°C) with 105000 x g. This fraction was suspended in an ice-cooled 100 mM potassium phosphate buffer solution (pH 7.4) (about 4 mg/ml protein concentration). This suspension was used as the enzyme solution.

[Table 7]

	Compound No.	Inhibitory Activity (IC ₅₀ , 10 ⁻⁹ M)
10	4-2	22
	4-8	11
	4-9	11
	4-10	11
15	4-12	11
	4-15	19
	4-18	18
	4-19	18
	4-20	17
20	4-21	11
	4-24	14
	4-26	15
	4-29	15
	4-30	12
25	4-31	20
	7	11
	8	12
	9	9.5
	13-2	18
30	17-1	13
	17-2	9.3
	17-3	11
	17-4	9.3
	18	15
35	19	32
	20	48
	21	26
	22	8.5
	23	12
40	24	17
	25	29
	27	20

As is clear from the above results, the compounds of this invention have an excellent squalene synthetase inhibitory activity.

Experimental Example 2

Assay of cholesterogenesis in the liver:

Cholesterol biosynthesis in the liver of a rat was assayed as follows. Six-week old Wistar fatty rats were given orally a test compound [Compound 4-2 (suspended in a 0.5% methyl cellulose solution)], while the control group was orally given only a 0.5% methyl cellulose solution. One hour later, sodium acetate labelled with radioisotope ^{14}C (manufactured by Amasham) was given intravenously at the tail (10 $\mu\text{Ci}/0.3\text{ ml}$ physiological saline/rat). One hour later, rats were sacrificed by decapitation, and 1.5 g of the first lobe of the liver was removed, which was saponified by immersing in 3.9 ml of an alkaline ethanol solution ($\text{KOH}:\text{EtOH}=1:2$) at 100°C for two hours, followed by extraction with 5 ml each portion of petroleum ether three times. The extract solution was dried, which was dissolved in 3 ml of ethanol:acetone (1:1). To the solution was added 2 ml of a 0.5% digitonin-ethanol solution. The mixture was left standing for one hour. Resulting precipitates were collected as total sterol, and the radioactivity was measured by means of a liquid scintillation counter. The results are shown below.

Amount given	Cholesterogenesis inhibitory rate (%)
0.6 mg/kg	80.1%
2.0 mg/kg	90.4%

As shown in the above results, the compound of this invention performs an excellent effect of inhibiting the cholesterogenesis by 80% or more.


Industrial Applicability

The compounds of this invention have a squalene

synthetase inhibitory activity, a cholesterol lowering activity and a triglyceride lowering activity, and are useful as a prophylactic and therapeutic agent of hyperlipemia as an agent of lowering lipids, and also
5 useful for prophylaxis and therapy of, among other, arteriosclerosis.

CLAIMS

1. A compound represented by the formula (I)




wherein R stands for a lower alkyl group optionally substituted by hydroxyl group which may be substituted, X stands for an optionally substituted carbamoyl group or an optionally substituted heterocyclic group having a deprotonatable hydrogen atom, R_1 stands for a lower alkyl group and W stands for a halogen atom, or a salt thereof.

2. The compound as claimed in claim 1, wherein R is C_{1-6} alkyl which may have 1 to 3 substituents selected from the group consisting of hydroxyl, acetyloxy, propionyloxy, t-butoxycarbonyloxy, palmitoyloxy, dimethylaminoacetyloxy and 2-aminopropionyloxy.
3. The compound as claimed in claim 1, wherein R is C_{3-6} branched alkyl which has 1 to 3 substituents selected from the group consisting of hydroxyl, acetyloxy, propionyloxy, t-butoxycarbonyloxy, palmitoyloxy, dimethylaminoacetyloxy and 2-aminopropionyloxy.
4. The compound as claimed in claim 1, wherein R is 2,2-dimethyl-3-hydroxypropyl, 3-hydroxy-2-hydroxymethyl-2-methylpropyl, 3-acetoxy-2,2-dimethylpropyl, 3-acetoxy-2-hydroxymethyl-2-methylpropyl or 3-acetoxy-2-acetoxymethyl-2-methylpropyl.
5. The compound as claimed in claim 1, wherein R_1 is methyl.
6. The compound as claimed in claim 1, wherein W is

chlorine atom.

7. The compound as claimed in claim 1, wherein X is a carbamoyl group represented by the formula



wherein R_2 and R_3 are independently

- (i) hydrogen,
- (ii) optionally substituted hydrocarbon group,
- (iii) optionally substituted heterocyclic group,

or

- (iv) acyl group

or R_2 and R_3 may form an optionally substituted 5 to 6 membered ring together with the adjacent nitrogen atom, said ring may contain 1 to 4 hetero atoms selected from nitrogen, oxygen and sulfur in addition to said nitrogen atom.

8. The compound as claimed in claim 7, wherein R_2 is hydrogen or C_{1-7} alkyl, R_3 is

(1) a hydrocarbon group selected from the group consisting of

- (a) C_{1-7} alkyl,
- (b) C_{3-7} cycloalkyl,
- (c) C_{2-6} alkenyl,
- (d) C_{6-10} aryl and
- (e) C_{6-10} aryl- C_{1-4} alkyl,

wherein each of said groups (a), (b) and (c) may have 1 to 4 substituents selected from the group consisting of

- (i) carboxyl which may be esterified with C_{1-6} alkyl or C_{6-10} aryl- C_{1-4} alkyl,
- (ii) phosphono group which may be mono- or di-substituted by C_{1-6} alkyl or C_{2-7} alkanoyloxy- C_{1-6} alkyl,
- (iii) sulfo group,
- (iv) sulfonamido which may be substituted by C_{1-6}

- alkyl or C₆₋₁₀ aryl-C₁₋₄ alkyl,
- (v) hydroxyl group which may be alkylated with C₁₋₃ alkyl,
- (vi) sulfhydryl group which may be alkylated with C₁₋₃ alkyl,
- (vii) carbamoyl,
- (viii) phenyl which may have 1 to 5 substituents selected from the group consisting of hydroxy, chlorine, fluorine, aminosulfonyl and amino which may be mono or di-substituted by C₁₋₃ alkyl,
- (ix) amino which may be mono- or di-substituted by C₁₋₃ alkyl,
- (x) cyclic amino group selected from the group consisting of piperidyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, piperazinyl, 4-methylpiperazinyl, 4-benzylpiperazinyl, 4-phenylpiperazinyl, 1,2,3,4-tetrahydroisoquinolinyl and phthalimido, each of said group may be substituted by C₁₋₃ alkyl, benzyl or phenyl and
- (xi) 5- to 6-membered heterocyclic group selected from the group consisting of pydiny, imidazolyl, indolyl and tetrazolyl,
- , and each of said group (d) and (e) may have 1 to 4 substituents selected from the group consisting of
- (i) carboxyl which may be esterified by C₁₋₄ alkyl,
- (ii) phosphono which may be mono- or di-substituted by C₁₋₆ alkyl or C₂₋₇ alkanoyloxy-C₁₋₆ alkyl,
- (iii) sulfo,
- (iv) C₁₋₄ alkylsulfonyl, C₆₋₁₀ arylsulfonyl or C₆₋₁₀ aryl-C₁₋₄ alkylsulfonyl,
- (v) sulfonamido which may be substituted by C₁₋₆ alkyl or C₆₋₁₀ aryl-C₁₋₄ alkyl,
- (vi) C₁₋₃ alkyl group which may be substituted by carboxyl group optionally esterified with C₁₋₄

alkyl, phosphono which may be mono- or di-substituted by C₁₋₆ alkyl, sulfo, sulfonamido which may be substituted by C₁₋₆ alkyl or C₆₋₁₀ aryl-C₁₋₄ alkyl and

(v) halogen,

(2) a heterocyclic group selected from the group consisting of tetrazolyl, 4,5-dihydro-5-oxo-1,2,4-oxadiazolyl, 4,5-dihydro-5-thioxo-1,2,4-oxadiazolyl, 2,3-dihydro-3-oxo-1,2,4-oxadiazolyl, 2,3-dihydro-3-thioxo-1,2,4-oxadiazolyl, 3,5-dioxo-1,2,4-oxadiazolidinyl, 4,5-dihydro-5-oxo-isoxazolyl, 4,5-dihydro-5-thioxo-isoxazolyl, 2,3-dihydro-2-oxo-1,3,4-oxadiazolyl, 2,3-dihydro-3-oxo-1,2,4-tetrazolyl and 2,3-dihydro-3-thioxo-1,2,4-tetrazolyl,

(3) an acyl group selected from the group consisting of

(i) C₂₋₇ alkanoyl which may be substituted by 1 to

2 halogen atoms,

(ii) C₆₋₁₀ arylsulfonyl,

(iii) C₁₋₄ alkylsulfonyl, and

(iv) C₆₋₁₀ aryl-C₁₋₄ alkylsulfonyl,

each of said group (ii), (iii) and (iv) may have 1 to 4 substituents selected from the group consisting of C₁₋₃ alkyl, C₁₋₃ alkoxy and halogen,

or R₂ and R₃ together with adjacent nitrogen form a 5- or 6- membered cyclic amino selected from the group consisting of piperazinyl, piperidyl, pyrrolidinyl, 2-oxo-piperazinyl, 2,6-dioxopiperazinyl, morpholinyl and thiomorpholinyl, each of said group may have 1 to 4 substituents selected from the group consisting of

(A) hydroxyl which may be substituted with C₁₋₃ alkyl or C₂₋₇ alkanoyl,

(B) carboxyl which may be substituted with C₁₋₆ alkyl or C₆₋₁₀ aryl-C₁₋₄ alkyl,

(C) phosphono which may be mono- or di-substituted by C₁₋₆ alkyl or C₂₋₇ alkanoyloxy-C₁₋₆ alkyl,

- (D) sulfo,
- (E) sulfonamido which may be substituted with C₁₋₆ alkyl or C₆₋₁₀ aryl-C₁₋₄ alkyl,
- (F) C₁₋₆ alkyl or C₂₋₅ alkenyl which may be substituted by
 - (i) carboxyl group which may be esterified with C₁₋₆ alkyl or C₆₋₁₀ aryl-C₁₋₄ alkyl,
 - (ii) phosphono group which may be mono- or di-substituted by C₁₋₆ alkyl or C₂₋₇ alkanoyloxy-C₁₋₆ alkyl,
 - (iii) sulfo group,
 - (iv) sulfonamido which may be substituted by C₁₋₆ alkyl or C₆₋₁₀ aryl-C₁₋₄ alkyl,
 - (v) hydroxyl group which may be alkylated with C₁₋₃ alkyl or C₂₋₇ alkanoyl,
 - (vi) sulfhydryl group which may be alkylated with C₁₋₃ alkyl,
 - (vii) carbamoyl,
 - (viii) phenyl which may have 1 to 5 substituents selected from the group consisting of hydroxy, halogen, aminosulfonyl and amino which may be substituted with C₁₋₃ alkyl and
 - (ix) amino which may be mono- or di-substituted by C₁₋₃ alkyl, or
 - (x) tetrazolyl,
- (G) amino which may be mono- or di-substituted with C₁₋₃ alkyl,
- (H) cyclic amino group selected from the group consisting of piperidyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, 4-methylpiperazinyl, 4-benzylpiperazinyl and 4-phenylpiperazinyl,
- (I) cyano,
- (J) carbamoyl,
- (K) oxo,
- (L) heterocyclic group selected from tetrazolyl and

2,5-dihydro-5-oxo-1,2,4-oxazolyl,

(M) carbamoyl substituted with C₁₋₄ alkylsulfonyl, C₆₋₁₀ arylsulfonyl or C₆₋₁₀ aryl-C₁₋₄ alkylsulfonyl,

(N) sulfhydryl which may be alkylated with C₁₋₃ alkyl and

(O) phenyl which may have 1 to 5 substituents selected from hydroxyl, halogen, aminosulfonyl and amino which may be substituted with C₁₋₃ alkyl.

9. The compound as claimed in claim 7, wherein R₂ and R₃ together with the adjacent nitrogen of the carbamoyl form a 5 to 6-membered ring selected from the group consisting of 1-piperazinyl, piperidino, 1-pyrrolidinyl, 2-oxo-1-piperazinyl and 2,6-dioxo-1-piperazinyl, each of the said group may have 1 to 2 substituents of C₁₋₆ alkyl which may be substituted by

(i) carboxyl which may be esterified with C₁₋₆ alkyl or C₆₋₁₀ aryl-C₁₋₄ alkyl,

(ii) phosphono group which may be mono- or di-substituted by C₁₋₆ alkyl or C₂₋₇ alkanoyl-C₁₋₆ alkyl,

(iii) sulfo group,

(iv) sulfonamido which may be substituted by C₁₋₆ alkyl or C₆₋₁₀ aryl-C₁₋₄ alkyl,

(v) hydroxyl group which may be alkylated by C₁₋₃ alkyl,

(vi) sulfhydryl which may be alkylated by C₁₋₃ alkyl,

(vii) carbamoyl,

(viii) phenyl which may have 1 to 5 substituents selected from the group consisting of hydroxy, halogen, aminosulfonyl and amino which may be substituted with C₁₋₃ alkyl,


(ix) amino which may be mono- or di-substituted by C₁₋₃ alkyl, or

(x) tetrazolyl.

10. The compound as claimed in claim 7, wherein R_2 is hydrogen or C_{1-7} alkyl and R_3 is C_{1-4} alkylsulfonyl.


11. The compound as claimed in claim 1, wherein the heterocyclic group represented by X is tetrazolyl, 4,5-dihydro-5-oxo-1,2,4-oxadiazolyl, 4,5-dihydro-5-thioxo-1,2,4-oxadiazolyl, 2,3-dihydro-3-oxo-1,2,4-oxadiazolyl, 2,3-dihydro-3-thioxo-1,2,4-oxadiazolyl, 3,5-dioxo-1,2,4-oxadiazolidinyl, 4,5-dihydro-5-oxo-isoxazolyl, 4,5-dihydro-5-thioxo-isoxazolyl, 2,3-dihydro-2-oxo-1,3,4-oxadiazolyl, 2,3-dihydro-3-oxo-1,2,4-tetrazolyl, or 2,3-dihydro-3-thioxo-1,2,4-tetrazolyl.

12. The compound as claimed in claim 1, wherein R_1 is methyl, W is chlorine atom, R is C_{3-6} branched alkyl which has 1 to 3 substituents selected from the group consisting of hydroxyl, acetyloxy, propionyloxy, t-butoxycarbonyloxy, palmitoyloxy, dimethylaminoacetyloxy and 2-aminopropionyloxy, and X is a carbamoyl group represented by the formula




wherein R_2' is hydrogen or C_{1-7} alkyl and R_3' is C_{1-4} alkyl.

13. The compound as claimed in claim 1, wherein R_1 is methyl, W is chlorine atom, R is C_{3-6} branched alkyl which has 1 to 3 substituents selected from the group consisting of hydroxyl, acetyloxy, propionyloxy, t-butoxycarbonyloxy, palmitoyloxy, dimethylaminoacetyloxy and 2-aminopropionyloxy, and X is a carbamoyl group represented by the formula



wherein R' is hydrogen or C₁₋₇ alkyl and n is an integer from 1 to 5.

14. The compound as claimed in claim 1, wherein R₁ is methyl, W is chlorine atom, R is C₃₋₆ branched alkyl which has 1 to 3 substituents selected from the group consisting of hydroxyl, acetyloxy, propionyloxy, t-butoxycarbonyloxy, palmitoyloxy, dimethylaminoacetyloxy and 2-aminopropionyloxy, and X is a carbamoyl group represented by the formula



wherein R'' is hydrogen or C₁₋₄ alkyl.

15. The compound as claimed in claim 1, wherein R₁ is methyl, W is chlorine atom, R is C₃₋₆ branched alkyl which has 1 to 3 substituents selected from the group consisting of hydroxyl, acetyloxy, propionyloxy, t-butoxycarbonyloxy, palmitoyloxy, dimethylaminoacetyloxy and 2-aminopropionyloxy, and X is tetrazolyl.

16. The compound as claimed in claim 1, which is (3R,5S)-N-methanesulfonyl-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetamide, (3R,5S)-N-methanesulfonyl-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2-hydroxymethyl-2-methylpropyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetamide, (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2-hydroxymethyl-2-methylpropyl)-2-oxo-N-[2-(pyrrolidin-

1-yl)ethyl]-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetamide,
(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-N-[2-(pyrrolidin-1-yl)ethyl]-1,2,3,5-tetrahydro-4,1-benzazepine-3-acetamide,
or a salt thereof.

17. The compound as claimed in claim 1, which is
(3R,5S)-N-methanesulfonyl-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetamide,
(3R,5S)-N-methanesulfonyl-1-(3-acetoxy-2-acetoxymethyl-2-methylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetamide,
N-[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]piperidine-4-acetic acid,
N-[(3R,5S)-1-(3-acetoxy-2-acetoxymethyl-2-methylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]piperidine-4-acetic acid,
N-[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]piperidine-4-acetic acid ethyl ester,
N-[(3R,5S)-1-(3-acetoxy-2-acetoxymethyl-2-methylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]piperidine-4-acetic acid ethyl ester or a salt thereof.

18. The compound as claimed in claim 1, which is
(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-1,2,3,5-tetrahydro-3-[1H(or 3H)-tetrazol-5-yl]methyl-4,1-benzoxazepine-3-one,
(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2-hydroxymethyl-2-methylpropyl)-1,2,3,5-tetrahydro-3-[1H(or 3H)-tetrazol-5-yl]methyl-4,1-benzoxazepine-3-

one,

(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-3-[1H(or 3H)-tetrazol-5-yl)methyl-4,1-benzoxazepine-3-one,
(3R,5S)-1-(3-acetoxy-2-acetoxymethyl-2-methylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-3-[1H(or 3H)-tetrazol-5-yl)methyl-4,1-benzoxazepine-3-one
or a salt thereof.

19. The compound as claimed in claim 1, which is
(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-neopentyl-2-oxo-N-[2-(pyrrolidin-1-yl)ethyl]-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetamide or a salt thereof.

20. The compound as claimed in claim 1, wherein
R is a lower alkyl group which may be substituted with
one or two hydroxyl groups,

X is carbamoyl group, which may have substituent(s) on
the nitrogen atom of the carbamoyl group,
said substituent being

(1) hydrocarbon selected from the group consisting of

- (a) C₁₋₇ alkyl,
- (b) C₃₋₇ cycloalkyl,
- (c) C₂₋₆ alkenyl,
- (d) C₆₋₁₀ aryl and
- (e) C₇₋₁₄ arylalkyl,

wherein each of said groups (a), (b) and (c) may have 1
to 4 substituents selected from the group consisting of

- (i) carboxyl which may be esterified with C₁₋₆
alkyl or C₇₋₁₀ arylalkyl,
- (ii) phosphono group,
- (iii) sulfo group,
- (iv) sulfonamido which may be substituted by C₁₋₆
alkyl or C₇₋₁₀ arylalkyl,
- (v) hydroxyl group which may be alkylated with C₁₋₃
alkyl,
- (vi) sulfhydryl group which may be alkylated with

- C₁₋₃ alkyl,
(vii) carbamoyl,
(viii) phenyl which may have substituent(s)
selected from the group consisting of hydroxyl,
chlorine, fluorine, aminosulfonyl and amino which
may be mono or di-substituted by C₁₋₃ alkyl,
(ix) amino which may be mono- or di-substituted by
C₁₋₃ alkyl,
(x) cyclic amino group selected from the group
consisting of piperidyl, pyrrolidinyl,
morpholinyl, thiomorpholinyl, piperazinyl, 4-
methylpiperazinyl, 4-benzylpiperazinyl and 4-
phenylpiperazinyl, each of said group may be
substituted by C₁₋₃ alkyl, benzyl or phenyl and
(xi) 5- to 6-membered heterocyclic group selected
from the group consisting of pyridinyl,
imidazolyl, indolyl and tetrazolyl,
, and each of said group (d) and (e) may have 1 to 4
substituents selected from the group consisting of
(i) carboxyl which may be esterified by C₁₋₄ alkyl,
(ii) phosphono,
(iii) sulfo,
(iv) sulfonamido which may be substituted by C₁₋₆
alkyl or C₇₋₁₀ arylalkyl,
(v) C₁₋₃ alkyl group which may be substituted by
carboxyl group optionally esterified with C₁₋₄
alkyl, phosphono, sulfo, or sulfonamido optionally
substituted with C₁₋₆ alkyl or C₇₋₁₀ arylalkyl, and
(vi) halogen.
- (2) a heterocyclic group selected from the group
consisting of tetrazolyl, 4,5-dihydro-5-oxo-1,2,4-
oxadiazolyl, 4,5-dihydro-5-thioxo-1,2,4-oxadiazolyl,
2,3-dihydro-3-oxo-1,2,4-oxadiazolyl, 2,3-dihydro-3-
thioxo-1,2,4-oxadiazolyl, 3,5-dioxo-1,2,4-
oxadiazolidinyl, 4,5-dihydro-5-oxo-isoxazolyl, 4,5-

dihydro-5-thioxo-isoxazolyl, 2,3-dihydro-2-oxo-1,3,4-oxadiazolyl, 2,3-dihydro-3-oxo-1,2,4-tetrazolyl and 2,3-dihydro-3-thioxo-1,2,4-tetrazolyl,

(3) an acyl group selected from the group consisting of

- (i) C₂₋₇ alkanoyl which may be substituted by 1 to 2 halogen atoms,
- (ii) C₆₋₁₀ arylsulfonyl,
- (iii) C₁₋₄ alkylsulfonyl, and
- (iv) C₇₋₁₄ arylalkylsulfonyl,

each of said group (ii), (iii) and (iv) may have 1 to 4 substituents selected from the group consisting of C₁₋₃ alkyl, C₁₋₃ alkoxy and halogen or

(4) cyclic amino carbonyl group, the cyclic amino group being selected from the group consisting of piperazinyl, piperidyl, pyrrolidinyl, 2-oxo-piperazinyl, 2,6-dioxopiperazinyl, morpholinyl and thiomorpholinyl, each of said group may have 1 to 4 substituents selected from the group consisting of

- (i) hydroxyl,
- (ii) carboxyl optionally esterified with C₁₋₄ alkyl,
- (iii) phosphono,
- (iv) sulfo,
- (v) sulfonamido optionally substituted with C₁₋₆ alkyl or C₇₋₁₀ arylalkyl,
- (vi) C₁₋₃ alkyl or C₂₋₅ alkenyl optionally substituted with (i), (ii), (iii), (iv) or (v) defined above,
- (vii) amino optionally mono- or di-substituted with C₁₋₃ alkyl,
- (viii) cyclic amino group selected from the group consisting of piperidyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, 4-methylpiperazinyl, 4-benzylpiperazinyl and 4-phenylpiperazinyl,
- (ix) cyano,

- (x) carbamoyl,
- (xi) oxo,
- (xii) C₁₋₃ alkoxy,
- (xiii) heterocyclic group selected from tetrazolyl and 2,5-dihydro-5-oxo-1,2,4-oxazolyl, and
- (xiv) carbamoyl substituted with C₆₋₁₀ arylsulfonyl, C₁₋₄ alkylsulfonyl or C₇₋₁₄ arylalkylsulfonyl.

21. A composition which comprises the compound as claimed in claim 1 and a pharmaceutically acceptable carrier.
22. A pharmaceutical composition for inhibiting squalene synthetase, which comprises the compound as claimed in claim 1 and a pharmaceutically acceptable carrier.
23. A pharmaceutical composition for lowering the level of triglyceride, which comprises the compound as claimed in claim 1 and a pharmaceutically acceptable carrier.
24. A pharmaceutical composition for lowering the lipid-level, which comprises the compound as claimed in claim 1 and a pharmaceutically acceptable carrier.
25. A pharmaceutical composition for prophylaxis or therapy of hyperlipidaemia, which comprises the compound as claimed in claim 1 and a pharmaceutically acceptable carrier.
26. Use of the compound as claimed in claim 1 for manufacturing a pharmaceutical composition.
27. Use of the compound as claimed in claim 1 for manufacturing a squalene synthetase inhibitor.
28. Use of the compound as claimed in claim 1 for manufacturing a pharmaceutical composition for lowering the level of triglyceride.
29. Use of the compound as claimed in claim 1 for manufacturing a pharmaceutical composition for lowering the lipid-level.

30. Use of the compound as claimed in claim 1 for manufacturing a pharmaceutical composition for prophylaxis or therapy of hyperlipidaemia or coronary sclerosis.


31. A method for inhibiting squalene synthetase in a mammal comprising administering an effective amount of the compound as claimed in claim 1 to said mammal.

32. A method for lowering the level of triglyceride in a mammal comprising administering an effective amount of the compound as claimed in claim 1 to said mammal.


33. A method for lowering the lipid-level in a mammal comprising administering an effective amount of the compound as claimed in claim 1 to said mammal.

34. A method for prophylaxis or therapy of hyperlipidaemia or coronary sclerosis in a mammal comprising administering an effective amount of the compound as claimed in claim 1 to said mammal.

35. A process for producing the compound as claimed in claim 1, wherein X is an optionally substituted carbamoyl group, which comprises reacting a compound of the formula:



wherein the symbols are as defined in claim 1, or a salt thereof with a compound of the formula:



wherein the symbols are as defined in claim 7, or a salt thereof.

36. The compound as claimed in claim 1, wherein R is
2,2-dimethyl-3-hydroxypropyl.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/JP 96/02596

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 C07D267/14 A61K31/55 C07D413/06 C07F9/38 C07D413/14 C07F9/40 A61K31/66		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 6 C07D A61K C07F		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,95 21834 (TAKEDA CHEMICAL INDUSTRIES, LTD.) 17 August 1995 see examples 1-9 ---	1,2,5-7
P,Y	EP,A,0 705 607 (TAKEDA CHEMICAL INDUSTRIES, LTD) 10 April 1996 see claims 1-32 ---	21-36
P,Y	EP,A,0 710 725 (TAKEDA CHEMICAL INDUSTRIES, LTD.) 8 May 1996 see claims 1-24 ---	1-36
Y	EP,A,0 567 026 (TAKEDA CHEMICAL INDUSTRIES, LTD.) 27 October 1993 see claims 1-24 --- -/-	1-36
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 29 November 1996		Date of mailing of the international search report 10.01.97
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer Herz, C

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/JP 96/02596

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>EP,A,0 645 377 (TAKEDA CHEMICAL INDUSTRIES, LTD.) 29 March 1995 see claims 1-9</p> <p>-----</p>	1-36

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/JP 96/02596

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9521834	17-08-95	AU-A- 1589895 JP-A- 7267939	29-08-95 17-10-95
EP-A-705607	10-04-96	AU-A- 3308195 FI-A- 954773 HU-A- 73422 JP-A- 8157369 NO-A- 953961	18-04-96 08-04-96 29-07-96 18-06-96 09-04-96
EP-A-710725	08-05-96	CA-A- 2161849 JP-A- 8205889	02-05-96 13-08-96
EP-A-567026	27-10-93	AU-A- 3700393 CA-A- 2094335 CN-A- 1083481 HU-A- 71482 JP-A- 6239843 NZ-A- 247429	21-10-93 21-10-93 09-03-94 28-11-95 30-08-94 27-06-95
EP-A-645377	29-03-95	AU-A- 7305194 CA-A- 2132792 CA-A- 2132794 CN-A- 1106397 EP-A- 0645378 FI-A- 944418 HU-A- 70962 JP-A- 7179444 JP-A- 7179429 NO-A- 943495	06-04-95 25-03-95 25-03-95 09-08-95 29-03-95 25-03-95 28-11-95 18-07-95 18-07-95 27-03-95

THIS PAGE BLANK (USPTO)